<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Paroxetine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Paroxetine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Paroxetine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9743" href="/d/html/9743.html" rel="external">see "Paroxetine: Drug information"</a> and <a class="drug drug_patient" data-topicid="10950" href="/d/html/10950.html" rel="external">see "Paroxetine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709196"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Suicidal thoughts and behaviors:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors. Paroxetine is not approved for use in pediatric patients.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F206594"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Brisdelle [DSC];</li>
<li>Paxil;</li>
<li>Paxil CR;</li>
<li>Pexeva [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867852"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT PARoxetine [DSC];</li>
<li>AG-Paroxetine;</li>
<li>APO-PARoxetine;</li>
<li>Auro-PARoxetine;</li>
<li>BIO-PARoxetine;</li>
<li>JAMP-PARoxetine;</li>
<li>M-Paroxetine;</li>
<li>Mar-PARoxetine;</li>
<li>MINT-Paroxetine;</li>
<li>NRA-Paroxetine;</li>
<li>PARoxetine-10;</li>
<li>PARoxetine-20;</li>
<li>PARoxetine-30;</li>
<li>Paxil;</li>
<li>Paxil CR;</li>
<li>PMS-PARoxetine;</li>
<li>Priva-PARoxetine [DSC];</li>
<li>RIVA-PARoxetine;</li>
<li>SANDOZ PARoxetine;</li>
<li>TARO-PARoxetine;</li>
<li>TEVA-PARoxetine</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1054737"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidepressant, Selective Serotonin Reuptake Inhibitor (SSRI)</span></li></ul></div>
<div class="block dop drugH1Div" id="F206618"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information: </b>Immediate-release paroxetine is available in two salts, hydrochloride (eg, Paxil) and mesylate (eg, Brisdelle, Pexeva); use extra precaution to ensure correct product selection. Paroxetine is available as immediate-release and extended-release formulations; both formulations are dosed once daily but are <b>not</b> interchangeable on a mg to mg basis; based on adult bioavailability data, immediate-release 10 mg is equivalent to extended-release 12.5 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14566199']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14566199'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cf110575-e58e-40d7-bc64-ed5b385ce732">Major depressive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar): </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>The use of paroxetine should be reserved for refractory cases when other options are ineffective or unacceptable/intolerable to the patient; therapy should not be initiated in a primary care setting; patients should be closely monitored for adverse effects (eg, suicidal thoughts/behaviors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29483201','lexi-content-ref-APA.1','lexi-content-ref-30397569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29483201','lexi-content-ref-APA.1','lexi-content-ref-30397569'])">Ref</a></span>). Therapy should be initiated at a low dose and titrated every 1 to 2 weeks based on response and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29483201','lexi-content-ref-30397569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29483201','lexi-content-ref-30397569'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: Immediate release (hydrochloride salt): Initial: 10 mg once daily; usual reported effective dose: 20 mg/day; maximum daily dose: 60 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29483201','lexi-content-ref-Keller.2001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29483201','lexi-content-ref-Keller.2001'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5359f530-bf85-41b9-82bc-913f7d455fcc">Obsessive-compulsive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Obsessive-compulsive disorder (OCD):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In the management of OCD in children and adolescents, if pharmacotherapy deemed necessary it should be in combination with cognitive behavioral therapy (CBT) and a selective serotonin reuptake inhibitor (SSRI) should be used first line; a preferred agent has not been identified (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22176943']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22176943'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥7 years and Adolescents &lt;18 years: Oral: Immediate release (hydrochloride salt): Initial: 10 mg once daily; titrate every 7 to 14 days in 10 mg/day increments; mean reported effective dose: 32 mg/day; maximum daily dose: 60 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22176943','lexi-content-ref-15502598','lexi-content-ref-10504818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22176943','lexi-content-ref-15502598','lexi-content-ref-10504818'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24aa5a69-6727-4715-b53a-79a3f9ae11c6">Social anxiety disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Social anxiety disorder: </b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In pediatric patients, selective serotonin reuptake inhibitor (SSRI) therapy is considered first-line pharmacologic treatment for moderate to severe anxiety disorders in combination with cognitive behavioral therapy (CBT); a preferred SSRI has not been defined; therapeutic selection should be based on pharmacokinetic and pharmacodynamic data, patient tolerability, cost, and unique risks/precautions with specific agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32439401']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32439401'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥8 years and Adolescents &lt;18 years: Oral: Immediate release (hydrochloride salt): Initial: 10 mg once daily; titrate at intervals of at least 7 days in 10 mg/day increments; maximum daily dose: 50 mg/<b>day</b>. Dosing based on a 16-week multicenter, randomized, double-blind, placebo-controlled trial that reported the efficacy of paroxetine in pediatric patients (aged 8 to 17 years) with social anxiety disorder; 163 patients were randomized to receive paroxetine; the overall mean dose was 21.7 mg/day for children and 26.1 mg/day for adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15520363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15520363'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> Consider planning discontinuation of therapy during lower-stress times, recognizing non-illness-related factors could cause stress or anxiety and be misattributed to OCD treatment discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29337001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29337001'])">Ref</a></span>). To discontinue therapy, gradually taper the dose to minimize the incidence of discontinuation syndromes (withdrawal) and allow for the detection of reemerging disease state symptoms (eg, relapse). Evidence supporting ideal taper rates after illness remission is sparse, particularly in pediatric patients; however, a general consensus is to taper over several weeks to months and to resume the previous OCD therapy if symptoms worsen; a plan for continued psychotherapy during serotonergic medication discontinuation is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29306047','lexi-content-ref-26554283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29306047','lexi-content-ref-26554283'])">Ref</a></span>). A unified taper protocol has been reported in adults with OCD in which serotonin reuptake inhibitor monotherapy was tapered over 12 weeks with biweekly psychiatrist visits (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29306047']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29306047'])">Ref</a></span>). For the treatment of depression, experts suggest tapering therapy over at least several weeks with consideration to the half-life of the antidepressant; agents with a shorter half-life may need to be tapered more conservatively and if intolerable discontinuation symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate; similar principles may also be applicable to OCD therapy discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-12479080','lexi-content-ref-19621834','lexi-content-ref-11347722','lexi-content-ref-22132433','lexi-content-ref-16683860','lexi-content-ref-15014601','lexi-content-ref-16913164']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-12479080','lexi-content-ref-19621834','lexi-content-ref-11347722','lexi-content-ref-22132433','lexi-content-ref-16683860','lexi-content-ref-15014601','lexi-content-ref-16913164'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Switching selective serotonin reuptake inhibitor (SSRI):</b> Evidence for ideal SSRI switching strategies in pediatric patients is sparse; strategies described in pediatric guidelines include a conservative approach (tapering and discontinuing the first SSRI before adding the second) and cross-titration (gradually discontinuing the first antidepressant while at the same time gradually increasing the new antidepressant). While consensus does not exist regarding which approach to utilize, it is important to note that the conservative approach runs the risk for exacerbation of symptoms or discontinuation syndrome; cross-titration may avoid these risks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32439401']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32439401'])">Ref</a></span>). Cross-titration (eg, over 1 to 4 weeks depending upon sensitivity to discontinuation symptoms and adverse effects) is standard for most switches, but is contraindicated when switching to or from a monamine oxidase inhibitor. While not as common of a strategy, a direct switch may be considered when switching to another agent in the same or similar class (eg, when switching between 2 SSRIs), when the antidepressant to be discontinued has been used for &lt;1 week, or when the discontinuation is for adverse effects. When choosing the switch strategy, consider the risk of discontinuation symptoms, potential for drug interactions, other antidepressant properties (eg, half-life, adverse effects, pharmacodynamics), and the degree of symptom control desired (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23459282','lexi-content-ref-23879318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23459282','lexi-content-ref-23879318'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51196599"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥7 years and Adolescents: Oral: There are no pediatric-specific recommendations; based on pharmacokinetics in adult patients, plasma concentration is 2 times that seen in normal function in mild to moderate renal impairment (CrCl 30 to 60 mL/minute), and in severe impairment (CrCl &lt;30 mL/minute) mean plasma concentration is ~4 times that seen in normal function; dosing adjustment suggested.</p></div>
<div class="block dohp drugH1Div" id="F51196600"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; based on pharmacokinetics in adult patients with hepatic dysfunction, plasma concentration is 2 times that seen in normal function; dosing adjustment suggested.</p></div>
<div class="block doa drugH1Div" id="F206599"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9743" href="/d/html/9743.html" rel="external">see "Paroxetine: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Some experts suggest a lower starting dose of 5 to 10 mg once daily (immediate release) or 12.5 mg once daily (extended release) and gradual titration in increments of ≤10 mg (immediate release) or 12.5 mg (extended release), particularly in patients with anxiety who are sensitive to antidepressant-associated overstimulation effects (eg, anxiety, insomnia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2019b','lexi-content-ref-Siris.2019','lexi-content-ref-Stein.2','lexi-content-ref-35900161']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2019b','lexi-content-ref-Siris.2019','lexi-content-ref-Stein.2','lexi-content-ref-35900161'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Paroxetine is available as IR and ER formulations; both formulations are dosed once daily but are <b>not</b> interchangeable on a milligram to milligram basis. Where dosing for the ER formulation is not provided for an indication, may convert between formulations using equivalence shown in "Dosing conversions" section below.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="88be5c8f-c670-41f5-94ab-670c50aba438">Body dysmorphic disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Body dysmorphic disorder (off-label use):</b> Dosing recommendations based on expert opinion: <i>Immediate release:</i> Oral: Initial: 20 mg once daily; may increase dose gradually based on response and tolerability in increments of 20 mg/day at intervals of every 2 to 3 weeks to a usual dose of 60 mg/day; doses up to 100 mg/day may be necessary in some patients for optimal response, typically under specialist care. <b>Note:</b> An adequate trial for assessment of effect in body dysmorphic disorder is 12 to 16 weeks, including maximum tolerated doses for at least 3 to 4 of those weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Phillips.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Phillips.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3acdc9e2-eb5e-47b3-8f22-12bd8ae32922">Generalized anxiety disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Generalized anxiety disorder:</b>
<i>Immediate release</i>
<i>:</i> Oral: Initial: 10 mg once daily; may increase dose based on response and tolerability in increments of 10 mg/day at intervals ≥1 week up to 50 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11411817','lexi-content-ref-22540422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11411817','lexi-content-ref-22540422'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cf110575-e58e-40d7-bc64-ed5b385ce732">Major depressive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release: </i>Oral: Initial: 20 mg once daily; may increase dose based on response and tolerability in increments of 10 to 20 mg/day at intervals ≥1 week to a maximum of 50 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2019c']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2019c'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release:</i> Oral: Initial: 25 mg once daily; may increase dose based on response and tolerability in increments of 12.5 mg/day at intervals ≥1 week to a maximum of 62.5 mg/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5359f530-bf85-41b9-82bc-913f7d455fcc">Obsessive-compulsive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Obsessive-compulsive disorder: </b>
<i>Immediate release</i>: Oral: Initial: 20 mg once daily; may increase dose based on response and tolerability in increments of 10 mg/day at intervals ≥1 week up to a recommended dose of 40 to 60 mg/day; maximum dose: 60 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17849776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17849776'])">Ref</a></span>). <b>Note:</b> An adequate trial for assessment of effect in obsessive-compulsive disorder is considered ≥6 weeks at the maximum tolerated dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27249090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27249090'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="35322c81-c95a-4c47-baaf-72001a1c63ee">Panic disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Panic disorder:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release:</i> Oral: Initial: 10 mg once daily for 3 to 7 days; may increase dose based on response and tolerability in increments of 10 mg/day at intervals ≥1 week up to a usual dose of 20 to 40 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stein.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stein.3'])">Ref</a></span>); maximum dose: 60 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release:</i> Oral: Initial: 12.5 mg once daily; may increase dose based on response and tolerability in increments of 12.5 mg/day at intervals ≥1 week up to a maximum of 75 mg/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="33aa39f3-80b9-497a-8725-78dfd54c167a">Posttraumatic stress disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Posttraumatic stress disorder:</b>
<i>Immediate release:</i> Oral: Initial: 20 mg once daily; may increase dose based on response and tolerability in increments of 10 to 20 mg/day at intervals ≥1 week up to 60 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16892419','lexi-content-ref-Stein.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16892419','lexi-content-ref-Stein.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="03008e1c-e898-491f-b522-256bb5260378">Premature ejaculation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Premature ejaculation (off-label use):</b>
<i>Immediate release:</i> Oral: Initial: 10 mg once daily; may increase dose based on response and tolerability in increments of 10 mg/day at intervals ≥1 week to a usual dosage of 20 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11386492']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11386492'])">Ref</a></span>). Some patients may require up to 40 mg/day for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25356302','lexi-content-ref-9126089']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25356302','lexi-content-ref-9126089'])">Ref</a></span>); some experts suggest 3- to 4-week titration intervals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Khera.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Khera.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c36dd6b3-72d8-44c0-9113-9b954af8885b">Premenstrual dysphoric disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Premenstrual dysphoric disorder: Note:</b> Some experts prefer selective serotonin reuptake inhibitors (SSRIs) other than paroxetine for this use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Casper.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Casper.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Continuous daily dosing regimen:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release (off-label):</i> Oral: Initial: 10 mg once daily; increase to usual effective dose of 20 mg once daily over the first month; in a subsequent menstrual cycle, a further increase to 40 mg/day may be necessary in some patients for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Casper.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Casper.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Extended release: </i>Oral: Initial: 12.5 mg once daily; increase to usual effective dose of 25 mg once daily over the first month; in a subsequent menstrual cycle, a further increase to 50 mg/day (based on equivalent IR dose) may be necessary in some patients for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Casper.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Casper.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Intermittent regimens:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">Luteal phase dosing regimen:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Immediate release (off-label):</i> Oral: Initial: 10 mg once daily during the luteal phase of menstrual cycle only (ie, beginning therapy 14 days before anticipated onset of menstruation and continued to the onset of menses); over the first month, may increase to usual effective dose of 20 mg once daily during the luteal phase; in a subsequent menstrual cycle, a further increase to 30 mg/day during the luteal phase may be necessary in some patients for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Casper.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Casper.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Extended release</i>: Oral: Initial: 12.5 mg once daily during the luteal phase of menstrual cycle only (ie, beginning therapy 14 days before anticipated onset of menstruation and continued to the onset of menses); over the first month, may increase to usual effective dose of 25 mg once daily during the luteal phase; in a subsequent menstrual cycle, a further increase to 37.5 mg/day (based on equivalent IR dose) during the luteal phase may be necessary in some patients for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Casper.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Casper.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Symptom-onset dosing regimen (off-label): <i>Immediate release:</i> Oral: Initial: 10 mg once daily from the day of symptom onset until a few days after the start of menses; over the first month, may increase dose based on response and tolerability up to 20 mg/day; in a subsequent menstrual cycle, a further increase to 30 mg/day may be necessary in some patients for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Casper.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Casper.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24aa5a69-6727-4715-b53a-79a3f9ae11c6">Social anxiety disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Social anxiety disorder:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release:</i> Oral: Initial: 10 mg once daily; may increase dose based on response and tolerability in increments of 10 mg/day at intervals ≥1 week to a maximum of 60 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10627793','lexi-content-ref-11838629','lexi-content-ref-8968300','lexi-content-ref-9728642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10627793','lexi-content-ref-11838629','lexi-content-ref-8968300','lexi-content-ref-9728642'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release:</i> Oral: Initial: 12.5 mg once daily; may increase dose based on response and tolerability in increments of 12.5 mg/day at intervals ≥1 week up to a maximum of 37.5 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> Doses up to 75 mg/day (based on equivalent IR dose) may be necessary in some patients for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11838629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11838629'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d79865ee-c341-481c-9766-0202b4671186">Vasomotor symptoms associated with menopause</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vasomotor symptoms associated with menopause (alternative agent): Note:</b> Nonhormonal alternative in patients unable or unwilling to take estrogen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22193145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22193145'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release</i>
<i>:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Capsule: Oral: 7.5 mg once daily at bedtime.</p>
<p style="text-indent:-2em;margin-left:6em;">Tablet (off-label): Oral: 10 to 20 mg once daily at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25107421','lexi-content-ref-16192581']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25107421','lexi-content-ref-16192581'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release</i>
<i>(off-label):</i> Oral: 12.5 to 25 mg once daily at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25107421','lexi-content-ref-12783913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25107421','lexi-content-ref-12783913'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosing conversions: </b> Immediate release 10 mg is equivalent to extended release 12.5 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14566199']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14566199'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Discontinuation of therapy<i>:</i></b> When discontinuing antidepressant treatment that has lasted for &gt;3 weeks, gradually taper the dose (eg, over 2 to 4 weeks) to minimize withdrawal symptoms and detect reemerging symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-25677972'])">Ref</a></span>). Reasons for a slower taper (eg, over 4 weeks) include use of a drug with a half-life &lt;24 hours (eg, paroxetine, venlafaxine), prior history of antidepressant withdrawal symptoms, or high doses of antidepressants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2019a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2019a'])">Ref</a></span>). If intolerable withdrawal symptoms occur, resume the previously prescribed dose and/or decrease dose at a more gradual rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15014601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15014601'])">Ref</a></span>). Select patients (eg, those with a history of discontinuation syndrome) on long-term treatment (&gt;6 months) may benefit from tapering over &gt;3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25677972'])">Ref</a></span>). Evidence supporting ideal taper rates is limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15014601','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15014601','lexi-content-ref-25677972'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Switching antidepressants:</b> Evidence for ideal antidepressant switching strategies is limited; strategies include cross-titration (gradually discontinuing the first antidepressant while at the same time gradually increasing the new antidepressant) and direct switch (abruptly discontinuing the first antidepressant and then starting the new antidepressant at an equivalent dose or lower dose and increasing it gradually). Cross-titration (eg, over 1 to 4 weeks depending upon sensitivity to discontinuation symptoms and adverse effects) is standard for most switches, but is contraindicated when switching to or from an MAOI. A direct switch may be an appropriate approach when switching to another agent in the same or similar class (eg, when switching between two SSRIs), when the antidepressant to be discontinued has been used for &lt;1 week, or when the discontinuation is for adverse effects. When choosing the switch strategy, consider the risk of discontinuation symptoms, potential for drug interactions, other antidepressant properties (eg, half-life, adverse effects, pharmacodynamics), and the degree of symptom control desired (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2019c','lexi-content-ref-23459282','lexi-content-ref-23879318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2019c','lexi-content-ref-23459282','lexi-content-ref-23879318'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Switching to or from an MAOI:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Allow 14 days to elapse between discontinuing an MAOI and initiation of paroxetine.</p>
<p style="text-indent:-2em;margin-left:6em;">Allow 14 days to elapse between discontinuing paroxetine and initiation of an MAOI.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991241"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;60 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to 60 mL/minute: There are no dosage adjustments provided in manufacturer's labeling; however, AUCs after a single paroxetine dose were approximately 2 times that of individuals with normal function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2530798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2530798'])">Ref</a></span>). Consider a 25% to 50% reduction in initial dose and titrate based on efficacy and tolerability, not to exceed the usual indication-specific maximum recommended dose (refer to dosing in adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22859791','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22859791','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: AUCs after a single paroxetine dose were ~3.5 times that of patients with normal kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2530798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2530798'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release:</i> Initial: 5 to 10 mg/day; increase if needed by increments of no more than 10 mg/day at intervals of at least 1 week based on efficacy and tolerability; maximum dose: 40 mg/day or the indication-specific maximum recommended dose (refer to dosing in adults), whichever is less (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22859791','lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22859791','lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Extended release:</i> Initial: 12.5 mg/day; increase if needed by 12.5 mg/day increments at intervals of at least 1 week based on efficacy and tolerability to a maximum dose of 50 mg/day or the indication-specific maximum recommended dose (refer to dosing in adults), whichever is less (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not likely to be significantly dialyzable due to large V<sub>d</sub> and high protein binding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Dose for CrCl &lt;30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15654172','lexi-content-ref-22859791','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15654172','lexi-content-ref-22859791','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not likely to be significantly dialyzable due to large V<sub>d</sub> and high protein binding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Dose for CrCl &lt;30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22859791','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22859791','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) and minimal residual kidney function unless otherwise noted. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Dose as for CrCl &lt;30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Dose as for CrCl &lt;30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988485"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: There are no dosage adjustments provided in manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release:</i> Initial: 10 mg/day; increase if needed by 10 mg/day increments at intervals of at least 1 week; maximum dose: 40 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release:</i> Initial: 12.5 mg/day; increase if needed by 12.5 mg/day increments at intervals of at least 1 week to a maximum of 37.5 mg/day (social anxiety disorder) or 50 mg/day (major depressive disorder, panic disorder).</p></div>
<div class="block arsc drugH1Div" id="F54446031"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Activation of mania or hypomania</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants (when used as monotherapy) may precipitate a mixed/manic episode in patients with bipolar disorder. Treatment-emergent <b>mania</b> or <b>hypomania</b> in patients with unipolar major depressive disorder (MDD) have been reported, as many cases of bipolar disorder present in episodes of MDD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23219059']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23219059'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; idiosyncratic. Unclear to what extent mood switches represent an uncovering of unrecognized bipolar disorder or a more direct pharmacologic effect independent of diagnosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23219059','lexi-content-ref-26667012','lexi-content-ref-19958306']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23219059','lexi-content-ref-26667012','lexi-content-ref-19958306'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; a systematic review observed that the risk of switching increased significantly within the initial 2 years of antidepressant treatment in patients with unipolar MDD receiving an antidepressant as monotherapy, but not thereafter (up to 4.6 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23219059']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23219059'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of bipolar disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Depressive episode with psychotic symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger age at onset of depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15289250','lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15289250','lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Antidepressant resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Female sex (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32215771','lexi-content-ref-29873955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32215771','lexi-content-ref-29873955'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bleeding risk</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Selective serotonin reuptake inhibitors (SSRIs) may increase the risk of bleeding, particularly if used concomitantly with antiplatelets and/or anticoagulants in adult and pediatric patients. Multiple observational studies have found an association with SSRI use and a variety of bleeding complications, ranging from bruising, <b>hematoma</b>, petechiae, purpuric disease, and epistaxis to <b>cerebrovascular accident</b>, upper GI bleeding (UGIB),<b> intracranial hemorrhage, </b>postpartum hemorrhage, and intraoperative bleeding, although conflicting evidence also exists (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30081645','lexi-content-ref-29536379','lexi-content-ref-28577352','lexi-content-ref-10755580','lexi-content-ref-14581256','lexi-content-ref-18460039','lexi-content-ref-28766108']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30081645','lexi-content-ref-29536379','lexi-content-ref-28577352','lexi-content-ref-10755580','lexi-content-ref-14581256','lexi-content-ref-18460039','lexi-content-ref-28766108'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Possibly via decreased platelet serotonin concentrations and inhibition of serotonin-mediated platelet activation leading to subsequent platelet dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21893349']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21893349'])">Ref</a></span>). SSRIs may also increase gastric acidity, which can increase the risk of GI bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30081645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30081645'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; bleeding risk is likely delayed for several weeks until SSRI-induced platelet serotonin depletion becomes clinically significant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21190637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21190637'])">Ref</a></span>), although the onset of bleeding may be more unpredictable if patients are taking concomitant antiplatelets, anticoagulants, or nonsteroidal anti-inflammatory drugs (NSAIDs). For UGIB, some studies have found risk to be the highest in the first 28 to 30 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19716436','lexi-content-ref-19491861']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19716436','lexi-content-ref-19491861'])">Ref</a></span>), whereas another study reported a median time of onset of 25 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17919277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17919277'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Concomitant use of anticoagulants and/or antiplatelets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21948719']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21948719'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Preexisting platelet dysfunction or coagulation disorders (eg, von Willebrand factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27508501','lexi-content-ref-17506225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27508501','lexi-content-ref-17506225'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Concomitant use of NSAIDs increases the risk for UGIB (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777151'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Fragility fractures</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Limited data from observational studies involving mostly older adults (≥50 years of age) suggest selective serotonin reuptake inhibitors (SSRIs) are associated with an increased risk of bone fractures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30247774','lexi-content-ref-22638709','lexi-content-ref-17242321','lexi-content-ref-22659406','lexi-content-ref-30964616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30247774','lexi-content-ref-22638709','lexi-content-ref-17242321','lexi-content-ref-22659406','lexi-content-ref-30964616'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Time-related; mechanism not fully elucidated; postulated to be through a direct effect by SSRIs on bone metabolism via interaction with 5-HT and osteoblast, osteocyte, and/or osteoclast activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22659406','lexi-content-ref-30775508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22659406','lexi-content-ref-30775508'])">Ref</a></span>). SSRIs may also contribute to fall risk, contributing to the incidence of fractures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27495351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27495351'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Delayed; risk appears to increase after initiation and may continue to increase with long-term use. A meta-analysis found risk of fracture increased from 2.9% over 1 year to 5.4% over 2 years; within 5 years, risk increased to 13.4% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30247774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30247774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Long-term use may be a risk factor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30247774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30247774'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyponatremia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Selective serotonin reuptake inhibitors (SSRIs) are associated with syndrome of inappropriate antidiuretic hormone secretion (<b>SIADH</b>) and/or <b>hyponatremia</b>, including severe cases, predominantly in the elderly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25262043','lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25262043','lexi-content-ref-16896026'])">Ref</a></span>). Hyponatremia is reversible with discontinuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8804257']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8804257'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> May cause SIADH via release of antidiuretic hormone (ADH) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>) or may cause nephrogenic SIADH by increasing the sensitivity of the kidney to ADH (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; usually develops within the first few weeks of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Concomitant use of diuretics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Low body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Lower baseline serum sodium concentration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Volume depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>History of hyponatremia (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Symptoms of psychosis (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ocular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Selective serotonin reuptake inhibitors (SSRIs) are associated with <b>acute angle-closure glaucoma </b>(AACG) in case reports and a case-controlled study. AACG may cause symptoms including eye pain, changes in vision, swelling, and redness, which can rapidly lead to permanent blindness if not treated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27993931']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27993931'])">Ref</a></span>). In addition, SSRIs may be associated with an increased risk of cataract development (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24631758','lexi-content-ref-20207418']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24631758','lexi-content-ref-20207418'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> AACG: Unclear; hypothesized SSRIs may increase the intraocular pressure via serotonergic effects on ciliary body muscle activation and pupil dilation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27135704','lexi-content-ref-27993931']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27135704','lexi-content-ref-27993931'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">For AACG:</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• ≥50 years of age (slight increase) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hyperopia (slight increase) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Personal or family history of AACG (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Inuit or Asian descent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Serotonin syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Serotonin syndrome</b> has been reported and typically occurs with coadministration of multiple serotonergic drugs. Only a handful of cases of serotonin syndrome have been reported with paroxetine monotherapy at therapeutic doses, in addition to a case which occurred following paroxetine overdose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31030620','lexi-content-ref-14742765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31030620','lexi-content-ref-14742765'])">Ref</a></span>). The diagnosis of serotonin syndrome is made based on the Hunter Serotonin Toxicity Criteria (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12925718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12925718'])">Ref</a></span>) and may result in a spectrum of symptoms, such as anxiety, agitation, confusion, delirium, hyperreflexia, muscle rigidity, myoclonus, tachycardia, tachypnea, and tremor. Severe cases may cause hyperthermia, significant autonomic instability (ie, rapid and severe changes in blood pressure and pulse), coma, and seizures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28148614','lexi-content-ref-15784664','lexi-content-ref-18759711']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28148614','lexi-content-ref-15784664','lexi-content-ref-18759711'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; overstimulation of serotonin receptors by serotonergic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28148614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28148614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; in the majority of cases (74%), onset occurred within 24 hours of treatment initiation, overdose, or change in dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10941349']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10941349'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of drugs that increase serotonin synthesis, block serotonin reuptake and/or impair serotonin metabolism (eg, monamine oxidase inhibitors [MAO inhibitors]). Of note, concomitant use of some serotonergic agents, such as MAO inhibitors, are contraindicated.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sexual dysfunction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Selective serotonin reuptake inhibitors (SSRIs) are commonly associated with<b> sexual disorders</b> in both men and women. The following adverse reactions have been associated with SSRI use: Ejaculatory delay, <b>orgasm disturbance</b>, erectile dysfunction, and<b> decreased libido </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955469','lexi-content-ref-26003261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955469','lexi-content-ref-26003261'])">Ref</a></span>). <b>Priapism </b>and decreased penile sensation have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17581442','lexi-content-ref-10665639','lexi-content-ref-29955469','lexi-content-ref-9818637','lexi-content-ref-26003261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17581442','lexi-content-ref-10665639','lexi-content-ref-29955469','lexi-content-ref-9818637','lexi-content-ref-26003261'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Increases in serotonin may affect other hormones and neurotransmitters involved in sexual function, in particular, testosterone's effect on sexual arousal and dopamine's role in achieving orgasm (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955469','lexi-content-ref-10333979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955469','lexi-content-ref-10333979'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Depression (sexual dysfunction is commonly associated with depression; SSRI-associated sexual dysfunction may be difficult to differentiate in treated patients) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12243609']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12243609'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidal thinking and behavior</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants are associated with an increased risk of <b>suicidal ideation</b> and <b>suicidal tendencies</b> in pediatric and young adult patients (18 to 24 years) in short-term studies. In adults &gt;24 years, short-term studies did not show an increased risk of suicidal thinking and behavior and in older adults ≥65 years of age, a decreased risk was observed. Although data have yielded inconsistent results regarding the association of antidepressants and risk of suicide, particularly among adults, collective evidence shows a trend of an elevated risk of suicidality in younger age groups (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16434782','lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227','lexi-content-ref-12668373','lexi-content-ref-18056231']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16434782','lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227','lexi-content-ref-12668373','lexi-content-ref-18056231'])">Ref</a></span>). Of note, the risk of a suicide attempt is inherent in major depression and may persist until remission occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not established; one of several postulated mechanisms is antidepressants may energize suicidal patients to act on impulses; another suggests that antidepressants may produce a worsening of depressive symptoms leading to the emergence of suicidal thoughts and actions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20553304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20553304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; increased risk observed in short-term studies (ie, &lt;4 months) in pediatric and young adults; it is unknown whether this risk extends to long-term use (ie, &gt;4 months).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Depression (risk of suicide associated with major depression and may persist until remission occurs)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Withdrawal syndrome</b>, consisting of both somatic symptoms (eg, dizziness, chills, light-headedness, vertigo, shock-like sensations, paresthesia, fatigue, headache, nausea, tremor, diarrhea, visual disturbances) and psychological symptoms (eg, anxiety, agitation, confusion, insomnia, irritability), have been reported, primarily following abrupt discontinuation in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Diler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Diler.1'])">Ref</a></span>). Withdrawal symptoms may also occur following gradual tapering (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25721705']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25721705'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Withdrawal; due to reduced availability of serotonin in the CNS with decreasing levels of the selective serotonin reuptake inhibitor (SSRI). Other neurotransmission systems, including increased glutamine and dopamine, may also be affected, as well as the hypothalamic-pituitary-adrenal axis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30501420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30501420'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; expected onset is 1 to 10 days (following either abrupt or tapered discontinuation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25721705','lexi-content-ref-30501420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25721705','lexi-content-ref-30501420'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt discontinuation (rather than gradual dosage reduction) of an antidepressant treatment that has lasted &gt;3 weeks, particularly a drug with a half-life &lt;24 hours (eg, paroxetine, venlafaxine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2019a','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2019a','lexi-content-ref-25677972'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of antidepressant withdrawal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2019a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2019a'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2019a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2019a'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F206558"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (5% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (≤15%)<span class="lexi-table-link-container"> (<a aria-label="Decreased Libido table link" class="lexi-table-link" data-table-id="lexi-content-decreased-libido" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-decreased-libido')">table 1</a>)</span><span class="table-link" style="display:none;">Decreased Libido</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Decreased Libido" frame="border" id="lexi-content-decreased-libido" rules="all">
<caption style="text-align:center;">
<b>Paroxetine: Adverse Reaction: Decreased Libido</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Paroxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Paroxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0% to 9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0% to 2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Females</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Multiple trials in a variety of conditions: MDD, OCD, PD, social anxiety disorder, GAD, and PTSD</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,822</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,340</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Multiple placebo-controlled clinical trials evaluating different components of sexual dysfunction</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6% to 15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0% to 5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Males</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Multiple trials in a variety of conditions: MDD, OCD, PD, social anxiety disorder, GAD, and PTSD</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,446</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,042</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Multiple placebo-controlled clinical trials evaluating different components of sexual dysfunction</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (2% to 16%), decreased appetite (1% to 12%), diarrhea (6% to 18%), dyspepsia (2% to 13%), nausea (17% to 26%), xerostomia (3% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Ejaculatory disorder (13% to 28%)<span class="lexi-table-link-container"> (<a aria-label="Ejaculatory Disorder table link" class="lexi-table-link" data-table-id="lexi-content-ejaculatory-disorder" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-ejaculatory-disorder')">table 2</a>)</span><span class="table-link" style="display:none;">Ejaculatory Disorder</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Ejaculatory Disorder" frame="border" id="lexi-content-ejaculatory-disorder" rules="all">
<caption style="text-align:center;">
<b>Paroxetine: Adverse Reaction: Ejaculatory Disorder</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Paroxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Paroxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13% to 28%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0% to 2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Multiple trials in a variety of conditions: MDD, OCD, PD, social anxiety disorder, GAD, and PTSD</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,446</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,042</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (12% to 22%), dizziness (6% to 14%), drowsiness (3% to 24%, less frequent in children and adolescents) (Safer 2006), headache (6% to 27%, including vascular headache), insomnia (7% to 24%), tremor (4% to 11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (3%), hypertension (≥1%), palpitations (2% to 3%), tachycardia (≥1%), vasodilation (2% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (≥1%), skin rash (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight gain (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (4% to 7%), dysgeusia (2%), flatulence (4% to 6%), increased appetite (2% to 4%), nausea and vomiting (4%), vomiting (2% to 3%; more frequent in children [two- to threefold] and adolescents) (Safer 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Abnormal orgasm (2% to 10%)<span class="lexi-table-link-container"> (<a aria-label="Abnormal Orgasm table link" class="lexi-table-link" data-table-id="lexi-content-abnormal-orgasm" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-abnormal-orgasm')">table 3</a>)</span><span class="table-link" style="display:none;">Abnormal Orgasm</span>, difficulty in micturition (3%), dysmenorrhea (5%), erectile dysfunction (2% to 10%)<span class="lexi-table-link-container"> (<a aria-label="Erectile Dysfunction table link" class="lexi-table-link" data-table-id="lexi-content-erectile-dysfunction" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-erectile-dysfunction')">table 4</a>)</span><span class="table-link" style="display:none;">Erectile Dysfunction</span>, female genital tract disease (2% to 10%), male genital disease (10%), urinary frequency (2% to 3%), urinary tract infection (2%), urination disorder (3%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Abnormal Orgasm" frame="border" id="lexi-content-abnormal-orgasm" rules="all">
<caption style="text-align:center;">
<b>Paroxetine: Adverse Reaction: Abnormal Orgasm</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Paroxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Paroxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2% to 9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0% to 1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Females</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Multiple trials in a variety of conditions: MDD, OCD, PD, social anxiety disorder, GAD, and PTSD</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,822</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,340</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Erectile Dysfunction" frame="border" id="lexi-content-erectile-dysfunction" rules="all">
<caption style="text-align:center;">
<b>Paroxetine: Adverse Reaction: Erectile Dysfunction</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Paroxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Paroxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2% to 9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0% to 3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Tablet</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Multiple trials in a variety of conditions: MDD, OCD, PD, social anxiety disorder, GAD, and PTSD</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,446</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,042</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5% to 10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0% to 3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Tablet, controlled release N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Multiple trials in a variety of conditions: MDD, panic disorder, and social anxiety disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">328</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">369</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (5% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (3% to 4%), agitation (3% to 5%), amnesia (2%), anxiety (2% to 5%), chills (2%), confusion (1%), depersonalization (3%), emotional lability (≥1%), fatigue (≤5%), hypomania (≤1%), intoxicated feeling (2%), lack of concentration (3% to 4%), lethargy (≤5%) malaise (≤5%), mania (≤1%), manic reaction (2%), myasthenia (1%), myoclonus (2% to 3%), nervousness (4% to 9%), paresthesia (4%), vertigo (≥1%), yawning (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (≥1%), back pain (3% to 5%), myalgia (2% to 5%), myopathy (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (4%), visual disturbance (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngeal edema (2%), pharyngitis (4%), rhinitis (3%), sinusitis (4% to 8%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, angina pectoris, atrial fibrillation, atrioventricular nodal arrhythmia, bradycardia, bundle branch block, edema, heart block, heart failure, hypotension, ischemic heart disease, orthostatic hypotension, peripheral edema, phlebitis, premature ventricular contractions, pulmonary embolism, supraventricular extrasystole, syncope, thrombophlebitis, thrombosis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, dermal ulcer, ecchymoses, eczema, erythema multiforme, erythema nodosum, exfoliative dermatitis, maculopapular rash, skin discoloration, skin hypertrophy, skin photosensitivity, urticaria, vesicobullous dermatitis, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Adrenergic syndrome, amenorrhea, dehydration, diabetes mellitus, heavy menstrual bleeding, hirsutism, hypercalcemia, hypercholesterolemia, hyperglycemia, hyperkalemia, hyperphosphatemia, hyperthyroidism, hypocalcemia, hypoglycemia, hypokalemia, hyponatremia (literature suggests incidence of hyponatremia among SSRIs ranges from &lt;1% to as high as 32%) (Gandhi 2017; Jacob 2006), hypothyroidism, increased libido, increased thirst, ketosis, thyroiditis, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Ageusia, aphthous stomatitis, bloody diarrhea, bruxism, cholelithiasis, colitis, dental bleeding (gums), duodenitis, dysphagia, enteritis, eructation, esophageal achalasia, esophagitis, fecal impaction, fecal incontinence, gastric ulcer, gastritis, gingivitis, glossitis, hematemesis, hiccups, ileitis, intestinal obstruction, melena, oral mucosal ulcer, oral paresthesia, peptic ulcer, peritonitis, rectal hemorrhage, sialadenitis, sialorrhea, stomatitis (including angular) (Verma 2012), tongue discoloration</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis, dysuria, epididymitis, hematuria, lactation, leukorrhea, mastitis, nocturia, oliguria, polyuria, pyuria, urinary incontinence, urinary retention, urinary urgency, urolithiasis, uterine hemorrhage, vaginal hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (hypochromic, microcytic, normocytic, and iron deficiency), basophilia, eosinophilia, hematoma, hypergammaglobulinemia, leukocytosis, leukopenia, lymphadenopathy, lymphedema, monocytosis, prolonged bleeding time, purpuric disease, thrombocytopenia, thrombocytosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic, hyperbilirubinemia, increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, facial edema, hypersensitivity reaction, tongue edema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait, akathisia, akinesia, altered sense of smell, antisocial behavior, aphasia, ataxia, bulimia nervosa, cerebral ischemia, cerebrovascular accident, choreoathetosis, delirium, delusion, depression with psychosis, drug dependence, dysarthria, euphoria, extrapyramidal reaction, hallucination, hostility, hyperacusis, hyperalgesia, hyperesthesia, hyperreflexia, hypertonia, hyporeflexia, hysteria, lack of emotion, manic depressive reaction, migraine, neuralgia, neuropathy, neurosis, paralysis, paranoid ideation, peripheral neuritis, psychosis, seizure, stupor, suicidal ideation, suicidal tendencies, trismus</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis, bursitis, dyskinesia, dystonia, fasciculations, gout, hypokinesia, muscle spasm, myelitis, myositis, osteoarthritis, osteoporosis, tenosynovitis, tetany, torticollis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Accommodation disturbance, amblyopia, anisocoria, blepharitis, blepharoptosis, cataract, conjunctival edema, corneal ulcer, diplopia, exophthalmos, keratoconjunctivitis, mydriasis, night blindness, nystagmus disorder, photophobia, retinal hemorrhage, visual field defect</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Deafness</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, nephritis, nephrolithiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma, bronchitis, dyspnea, epistaxis, hemoptysis, pneumonia, pulmonary edema, pulmonary emphysema, pulmonary fibrosis, stridor</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Torsades de pointes (Wenzel-Seifert 2011), vasculitis (Margolese 2001; Welsh 2006), ventricular fibrillation (Lee 2018), ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Mameli 2013), hyperhidrosis, Stevens-Johnson syndrome, toxic epidermal necrolysis (Ahmed 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Galactorrhea not associated with childbirth (Gonzales 2000; Morrison 2001), hyperprolactinemia (Evrensel 2016), porphyria, SIADH (Gandhi 2017), uncontrolled diabetes mellitus</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acute pancreatitis, hemorrhagic pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Preeclampsia, priapism (Ahmad 1995), sexual disorder (Montejo 2019; Montejo-Gonzalez 1997)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, bone marrow aplasia, hemolytic anemia, Henoch-Schönlein purpura, immune thrombocytopenia, pancytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure, hepatic necrosis, hepatotoxicity (Azaz-Livshits 2002; Benbow 1997)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, drug reaction with eosinophilia and systemic symptoms, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior (Nishida 2008; Sharma 2016), anosmia (including hyposmia), cogwheel rigidity, disorientation (Wakeno 2007), Guillain-Barre syndrome, homicidal ideation (Moore 2010), hyperactive behavior (including hyperkinetic muscle activity; more frequent in children [two- to threefold] and adolescents) (Safer 2006), intracranial hemorrhage (Douros 2018), neuroleptic malignant syndrome (with drug interactions) (Tanii 2006; Uguz 2013), restless leg syndrome (Rottach 2008; Sanz-Fuentenebro 1996), restlessness (Naslund 2017), serotonin syndrome (Hudd 2020; Velez 2004), status epilepticus (Taniguchi 2014), withdrawal syndrome (Fava 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bradykinesia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Acute angle-closure glaucoma (Eke 1997; Kirwan 1997; Lewis 1997), optic neuritis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Hypersensitivity pneumonitis (Maia 2015), laryngismus, pulmonary alveolitis (allergic), pulmonary hypertension</p></div>
<div class="block coi drugH1Div" id="F206574"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, anaphylaxis, angioedema, Stevens-Johnson syndrome) to paroxetine or any component of the formulation; concurrent use with or within 14 days of monoamine oxidase inhibitors (including linezolid or methylene blue IV); concomitant use with pimozide or thioridazine; pregnancy (Brisdelle only).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Initiation of paroxetine within 2 weeks of pimozide or thioridazine discontinuation.</p></div>
<div class="block war drugH1Div" id="F206555"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Akathisia: Inability to remain still due to feelings of agitation or restlessness has been observed with paroxetine and other selective serotonin reuptake inhibitors (SSRIs). Usually occurs within the first few weeks of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Anticholinergic effects: Has low potential for sedation and anticholinergic effects relative to cyclic antidepressants; however, among the SSRI class these effects are relatively higher.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease; paroxetine has not been systemically evaluated in patients with a recent history of myocardial infarction or unstable heart disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; clearance is decreased and plasma concentrations are increased; a lower dosage may be needed. However, selective serotonin reuptake inhibitors such as paroxetine are considered the safest antidepressants to use in chronic liver disease because of their relative lack of side effects and high therapeutic index (Mullish 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; clearance is decreased and plasma concentrations are increased; a lower dosage may be needed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients with seizure disorder.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Brisdelle: Brisdelle contains a lower dose than what is required for the treatment of psychiatric conditions. Patients who require paroxetine for the treatment of psychiatric conditions should discontinue Brisdelle and begin treatment with a paroxetine-containing medication which provides an adequate dosage.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878580"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block prod-avail drugH1Div" id="F58523423"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Pexeva has been discontinued in the United States for &gt;1 year.</p></div>
<div class="block foc drugH1Div" id="F206567"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as mesylate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Brisdelle: 7.5 mg [DSC] [contains fd&amp;c red #40 (allura red ac dye), fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 7.5 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral, as hydrochloride [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Paxil: 10 mg/5 mL (250 mL) [contains fd&amp;c yellow #6(sunset yellow)alumin lake, methylparaben, propylene glycol, propylparaben, saccharin sodium; orange flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/5 mL (250 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Paxil: 10 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Paxil: 10 mg [scored; contains fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Paxil: 20 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Paxil: 20 mg [scored; contains fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Paxil: 30 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Paxil: 30 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Paxil: 40 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Paxil: 40 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg, 30 mg, 40 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as mesylate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pexeva: 10 mg [DSC], 20 mg [DSC], 30 mg [DSC], 40 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as hydrochloride [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Paxil CR: 12.5 mg [contains fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Paxil CR: 25 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Paxil CR: 25 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Paxil CR: 37.5 mg [DSC] [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Paxil CR: 37.5 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 12.5 mg, 25 mg, 37.5 mg</p></div>
<div class="block geq drugH1Div" id="F206551"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F206577"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (PARoxetine Mesylate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg (per each): $6.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (PARoxetine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/5 mL (per mL): $1.58</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Paxil Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/5 mL (per mL): $2.13</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (PARoxetine HCl ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg (per each): $0.80 - $5.58</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.86 - $5.82</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">37.5 mg (per each): $0.92 - $5.99</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Paxil CR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg (per each): $11.04</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $11.52</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">37.5 mg (per each): $11.87</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (PARoxetine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $1.95 - $2.67</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $2.29 - $2.73</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $2.70 - $2.83</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $2.88 - $3.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Paxil Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $10.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $11.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $11.52</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $12.17</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867853"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Paxil: 10 mg, 20 mg, 30 mg [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg, 30 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as hydrochloride [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Paxil CR: 12.5 mg [contains fd&amp;c yellow #6(sunset yellow)alumin lake, polysorbate 80, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Paxil CR: 25 mg [contains polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F52613535"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to meals; administration with food may decrease GI side effects; shake suspension well before use. Paxil should preferentially be administered in the morning. Do not chew or crush immediate- or controlled-release tablet; swallow whole.</p></div>
<div class="block adm drugH1Div" id="F206571"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May be administered without regard to meals. Administer preferably in the morning; when used for vasomotor symptoms of menopause, administer at bedtime. Do not crush, break, or chew ER or IR film-coated tablets. Shake suspension well before use.</p>
<p style="text-indent:-2em;margin-left:2em;">Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. ER tablets should be swallowed whole. IR tablet, capsule, and oral suspension formulations are available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery.</p></div>
<div class="block hazard drugH1Div" id="F49104563"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F206588"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Capsules: Store between 20°C and 25°C (68°F and 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). Protect from light and humidity.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Store between 20°C and 25°C (68°F and 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension: Store at or below 25°C (77°F).</p></div>
<div class="block meg drugH1Div" id="F7874764"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Brisdelle:<a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F204516s013lbl.pdf%23page%3D18&amp;token=kXTsO7Vfc%2BAqIhW7NQckTuDggW8cjj4ekcTZT1WxP2E5TEZvm4SFWCHxK%2BaRi0sJPbB6Wnx%2BjZ4E6ylVS0rG15eHaBYiPDtOHMQaiRLiH0L5stfaNpI7kidxMRS7dKJK&amp;TOPIC_ID=12681" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204516s013lbl.pdf#page=18</a></p>
<p style="text-indent:-2em;margin-left:4em;">Paxil: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F020031s082%2C020710s050lbl.pdf%23page%3D39&amp;token=1noV43BEU7iEXA16qj0RQCX%2ByvNTxoospX2dUHqzqNP%2FX5bf4qylelholPuYij%2BW8TPVCIJRRPMtObfJohdvOOuJMUcT7GT3knqQROpbzU3U0w91chvw3D6dCw%2Fq9gfT&amp;TOPIC_ID=12681" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020031s082,020710s050lbl.pdf#page=39</a></p>
<p style="text-indent:-2em;margin-left:4em;">Paxil CR: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F020936s057s064lbl.pdf%23page%3D30&amp;token=wZvL3CeqyeWbN5Zb8QiAplLu2875gP9aq7%2B793YTTvNBOQ2N%2BJFIKvp7umyCB9AD%2F%2Bm%2BNwjLOlc3gwDF9MMvjXEwEzVPBpTUWVXegv5GbnncrfCLTQ%2BrBrpu7pNQlMlI&amp;TOPIC_ID=12681" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020936s057s064lbl.pdf#page=30</a></p>
<p style="text-indent:-2em;margin-left:4em;">Pexeva: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F021299s035s038lbl.pdf%23page%3D18&amp;token=X4bClVjlMUqJqHs36H2IFdP0RSgG%2BSPwmIk9qSf%2FVFPWOw74aglJluYprKk5cqBlha36q78wEHxuGu0DWq9sX5nn0UVjw7GYO20QZ5xBhQ2aTZ8PPNqYBk9zL06jwRjH&amp;TOPIC_ID=12681" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021299s035s038lbl.pdf#page=18</a></p></div>
<div class="block usep drugH1Div" id="F53568236"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Brisdelle: Treatment of moderate to severe vasomotor symptoms associated with menopause (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Paxil: Treatment of major depressive disorder (MDD), panic disorder (with or without agoraphobia), obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), and post-traumatic stress disorder (All indications: FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Paxil CR: Treatment of MDD, panic disorder (with or without agoraphobia), social anxiety disorder (social phobia), and premenstrual dysphoric disorder (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Pexeva: Treatment of MDD, OCD, panic disorder (with or without agoraphobia), and GAD (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F206646"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">PARoxetine may be confused with DULoxetine, FLUoxetine, PACLitaxel, piroxicam, pyridoxine, vortioxetine</p>
<p style="text-indent:-2em;margin-left:4em;">Paxil may be confused with Doxil, PACLitaxel, Plavix, PROzac, Taxol, Trexall</p>
<p style="text-indent:-2em;margin-left:4em;">Pexeva [DSC] may be confused with Lexiva</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Paroxetine is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its strong anticholinergic properties and potential for sedation and orthostatic hypotension. In addition, use the SSRIs with caution due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F206630"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2D6 (strong)</p></div>
<div class="block dri drugH1Div" id="F206560"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Abrocitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Blood Glucose Lowering Effects: Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Ajmaline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol.  Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Almotriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may increase the serum concentration of Amphetamines. Management: Monitor for amphetamine toxicities, including serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability). Initiate amphetamines at lower doses, monitor frequently, and adjust dose as needed.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiplatelet Agents (P2Y12 Inhibitors): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents: Serotonergic Agents (High Risk) may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: Aripiprazole dose reductions or avoidance are required for indications other than major depressive disorder. Dose adjustments vary based on formulation, initial starting dose, and the additional use of CYP3A4 inhibitors. See interact monograph for details<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil.  Management: Decrease aripiprazole lauroxil dose to next lower strength if used with strong CYP2D6 inhibitors for over 14 days. No dose adjustment needed if using the lowest dose (441 mg) or if a CYP2D6 PM. Max dose is 441 mg if also taking strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asenapine: May increase the serum concentration of PARoxetine. Management: Decrease the paroxetine dose by half when used concomitantly with asenapine. Monitor patients receiving this combination closely for signs and symptoms of increased paroxetine toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aspirin: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Atomoxetine.  Management: Initiate atomoxetine at a reduced dose (patients who weigh up to 70 kg: 0.5 mg/kg/day; adults or patients who weigh 70 kg or more: 40 mg/day) in patients receiving a strong CYP2D6 inhibitor. Increase to usual target dose after 4 weeks if needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bemiparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Bemiparin.  Management: Avoid concomitant use of bemiparin with antiplatelet agents. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: Selective Serotonin Reuptake Inhibitors may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Brexpiprazole.  Management: Reduce brexpiprazole dose to 50% of usual with strong CYP2D6 inhibitors, reduce to 25% of usual if used with both a strong CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor; these recommendations do not apply if treating major depressive disorder<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Broom: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Broom. Specifically, the concentrations of sparteine, a constituent of broom, may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: May enhance the adverse/toxic effect of PARoxetine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Caplacizumab. Specifically, the risk of bleeding may be increased.  Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carvedilol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Carvedilol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorpheniramine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Chlorpheniramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of PARoxetine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: May enhance the antiplatelet effect of Selective Serotonin Reuptake Inhibitors. Citalopram may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyclobenzaprine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of PARoxetine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase the serum concentration of PARoxetine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyproheptadine: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Do not use serotonergic agents (high risk) with dapoxetine or within 7 days of serotonergic agent discontinuation. Do not use dapoxetine within 14 days of monoamine oxidase inhibitor use. Dapoxetine labeling lists this combination as contraindicated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darunavir: May decrease the serum concentration of PARoxetine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deutetrabenazine: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Deutetrabenazine.  Management: The total daily dose of deutetrabenazine should not exceed 36 mg with concurrent use of a strong CYP2D6 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate-Methylphenidate: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dextromethorphan: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may increase the serum concentration of Dextromethorphan. Management: Consider alternatives to this drug combination. The dose of dextromethorphan/bupropion product should not exceed 1 tablet once daily. Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): CYP2D6 Inhibitors (Strong) may increase the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: May enhance the antiplatelet effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). DULoxetine may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may increase the serum concentration of DULoxetine. Management: Monitor for increased duloxetine effects/toxicities and signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperthermia, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eletriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Eliglustat.  Management: Eliglustat dose is 84 mg daily with CYP2D6 inhibitors. Use is contraindicated (COI) when also combined with strong CYP3A4 inhibitors. When also combined with a moderate CYP3A4 inhibitor, use is COI in CYP2D6 EMs or IMs and should be avoided in CYP2D6 PMs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxaparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Enoxaparin.  Management: Discontinue antiplatelet agents prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenfluramine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Fenfluramine.  Management: Limit fenfluramine dose to 20 mg/day without concurrent stiripentol or to 17 mg/day with concomitant stiripentol and clobazam when used with a strong CYP2D6 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fesoterodine: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flecainide: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Flecainide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FLUoxetine: May enhance the antiplatelet effect of PARoxetine. FLUoxetine may enhance the serotonergic effect of PARoxetine. This could result in serotonin syndrome. FLUoxetine may increase the serum concentration of PARoxetine. PARoxetine may increase the serum concentration of FLUoxetine. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes), bleeding, and increased SSRI toxicities when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluPHENAZine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of FluPHENAZine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: May decrease the serum concentration of PARoxetine. The active metabolite amprenavir is likely responsible for this effect.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Galantamine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Galantamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Gefitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Avoid use of this combination if possible. If the combination cannot be avoided, monitor closely for evidence of reduced response to the selective serotonin reuptake inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Heparin.  Management: Decrease the dose of heparin or agents with antiplatelet properties if coadministration is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iboga: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Iboga. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP2D6 inhibitor and monitor for increased iloperidone toxicities, including QTc interval prolongation and arrhythmias.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Indoramin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ioflupane I 123: Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lasmiditan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Lofexidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorcaserin (Withdrawn From US Market): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maprotiline: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Maprotiline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Mequitazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metaxalone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylene Blue: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Metoclopramide.  Management: For gastroparesis: reduce metoclopramide dose to 5mg 4 times/day and limit to 20mg/day; nasal spray not recommended.  For GERD: reduce metoclopramide dose to 5mg 4 times/day or to 10mg 3 times/day and limit to 30mg/day. Monitor for toxicity when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoprolol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Metoprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mexiletine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Mexiletine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors (Antidepressant): Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Monoamine Oxidase Inhibitors (Antidepressant). This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nebivolol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Nicergoline. Specifically, concentrations of the MMDL metabolite may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Nicergoline. Specifically, concentrations of the MDL metabolite may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.  Management: Consider alternatives to NSAIDs. Monitor for evidence of bleeding and diminished antidepressant effects. It is unclear whether COX-2-selective NSAIDs reduce risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the antiplatelet effect of Selective Serotonin Reuptake Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may increase the serum concentration of Oliceridine. Management: Monitor for increased opioid effects (eg, respiratory depression, sedation) and for serotonin syndrome/serotonin toxicity when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists (metabolized by CYP3A4 and CYP2D6): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may diminish the therapeutic effect of Opioid Agonists (metabolized by CYP3A4 and CYP2D6). Management: Monitor for decreased therapeutic response (eg, analgesia) and opioid withdrawal when coadministered with SSRIs that strongly inhibit CYP2D6. Additionally, monitor for serotonin syndrome/serotonin toxicity if these drugs are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists (metabolized by CYP3A4): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxitriptan: Serotonergic Agents (High Risk) may enhance the serotonergic effect of Oxitriptan. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the adverse/toxic effect of Serotonergic Agents (High Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perhexiline: PARoxetine may increase the serum concentration of Perhexiline. Perhexiline may increase the serum concentration of PARoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perphenazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Perphenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Pitolisant.  Management: Reduce the pitolisant dose by 50% if a strong CYP2D6 inhibitor is initiated. For patients receiving strong CYP2D6 inhibitors, initiate pitolisant at 8.9 mg once daily and increase after 7 days to a maximum of 17.8 mg once daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pravastatin: May enhance the adverse/toxic effect of PARoxetine. Specifically, blood glucose elevations may occur with the combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primaquine: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Primaquine. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Primaquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procyclidine: PARoxetine may increase the serum concentration of Procyclidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propranolol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Propranolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rasagiline: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Rasagiline. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: CYP2D6 Inhibitors (Strong) may increase the serum concentration of RisperiDONE.  Management: Careful monitoring for risperidone toxicities and possible dose adjustment are recommended when combined with strong CYP2D6 inhibitors. See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Safinamide: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Use the lowest effective dose of SSRIs in patients treated with safinamide and monitor for signs and symptoms of serotonin syndrome/serotonin toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of other Selective Serotonin Reuptake Inhibitors. Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of other Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selegiline: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Selegiline. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk, Miscellaneous): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Non-Opioid CNS Depressants: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Opioids (High Risk): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Serotonin/Norepinephrine Reuptake Inhibitors. Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Sertindole.  Management: Consider alternatives to this combination when possible. If combined, consider using lower doses of sertindole and monitor the ECG closely for evidence of QTc interval prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of Serotonergic Agents (High Risk). Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Syrian Rue: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Avoid concurrent use of strong CYP2D6 inhibitors with tamoxifen when possible, as the combination may be associated with a reduced clinical effectiveness of tamoxifen.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamsulosin: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrabenazine: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased.  Management: Limit the tetrabenazine dose to 50 mg per day (25 mg per single dose) in patients taking strong CYP2D6 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Selective Serotonin Reuptake Inhibitors may enhance the hyponatremic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Thioridazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Selective Serotonin Reuptake Inhibitors may diminish the therapeutic effect of Thyroid Products. Thyroid product dose requirements may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Timolol (Ophthalmic): CYP2D6 Inhibitors (Strong) may increase the serum concentration of Timolol (Ophthalmic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Timolol (Systemic): CYP2D6 Inhibitors (Strong) may increase the serum concentration of Timolol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolterodine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tolterodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may enhance the adverse/toxic effect of TraMADol. Specifically, the risk for serotonin syndrome/serotonin toxicity and seizures may be increased. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may diminish the therapeutic effect of TraMADol.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes), seizures, and decreased tramadol efficacy when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: PARoxetine may enhance the serotonergic effect of Tricyclic Antidepressants. PARoxetine may increase the serum concentration of Tricyclic Antidepressants.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased TCA concentrations/effects if these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Valbenazine.  Management: Reduce valbenazine dose to 40 mg once daily when combined with a strong CYP2D6 inhibitor. Monitor for increased valbenazine effects/toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vasopressin: Drugs Suspected of Causing SIADH may enhance the therapeutic effect of Vasopressin. Specifically, the pressor and antidiuretic effects of vasopressin may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venlafaxine: May enhance the antiplatelet effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). Venlafaxine may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may decrease serum concentrations of the active metabolite(s) of Venlafaxine. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may increase the serum concentration of Venlafaxine. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine: Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may enhance the antiplatelet effect of Vortioxetine. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may enhance the serotonergic effect of Vortioxetine. This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may increase the serum concentration of Vortioxetine.  Management: Consider alternatives to this drug combination. If combined, reduce the vortioxetine dose by half and monitor for signs and symptoms of bleeding and serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, autonomic instability).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F206589"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;text-align:justify;display:inline">Peak concentration is increased, but bioavailability is not significantly altered by food. Management: Administer without regard to meals. </p></div>
<div class="block rep_considerations drugH1Div" id="F55499030"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Paroxetine is approved for the treatment of generalized anxiety disorder, panic disorder, posttraumatic stress disorder, social anxiety disorder, unipolar major depressive disorder, and obsessive-compulsive disorder. If treatment for any of these indications is initiated for the first time in a patient planning to become pregnant, agents other than paroxetine are recommended (use of paroxetine is not preferred for use during pregnancy) (Larsen 2015; WFSBP [Bandelow 2012]).</p>
<p style="text-indent:0em;margin-top:2em;">Paroxetine is also approved for the treatment of premenstrual dysphoric disorder. For patients attempting to conceive, symptom-onset dosing may be beneficial to minimize potential fetal exposure (Ismaili 2016; Lanza di Scalea 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Selective serotonin reuptake inhibitors (SSRIs) may be associated with male and female treatment-emergent sexual dysfunction (Coskuner 2018; WFSBP [Bauer 2013]). Decreased libido and orgasmic disturbances have been reported in females; abnormal ejaculation, decreased libido, and impotence have been reported in males with use. This may also be a manifestation of the psychiatric disorder. The actual risk associated with paroxetine is not known; however, the risk of treatment-emergent sexual dysfunction may be greater with paroxetine than other SSRIs. SSRI-related sexual dysfunction may resolve with dose reduction or discontinuation of the SSRI; in some cases, sexual dysfunction may persist once therapy is discontinued (Coskuner 2018; Jing 2016; Waldinger 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Paroxetine is used off label for the treatment of premature ejaculation. Although data are limited, some studies have shown SSRIs may impair the motility of spermatozoa; therefore, use of other treatments may be preferred in males planning to father a child (Althof 2014; Siroosbakht 2019; Sylvester 2019).</p></div>
<div class="block pri drugH1Div" id="F206578"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Paroxetine crosses the placenta (Hendrick 2003).</p>
<p style="text-indent:0em;margin-top:2em;">As a class, selective serotonin reuptake inhibitors (SSRIs) have been evaluated extensively in pregnant patients. Studies focusing on newborn outcomes following first trimester exposure often have inconsistent results due to differences in study design and confounders such as maternal disease and social factors (Anderson 2020; Biffi 2020; Fitton 2020; Reefhuis 2015; Womersley 2017). Adverse effects in the newborn following SSRI exposure late in the third trimester can include apnea, constant crying, cyanosis, feeding difficulty, hyperreflexia, hypo- or hypertonia, hypoglycemia, irritability, jitteriness, respiratory distress, seizures, temperature instability, tremor, and vomiting. Prolonged hospitalization, respiratory support, or tube feedings may be required. Symptoms may be due to the toxicity of the SSRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with SSRI treatment. Persistent pulmonary hypertension of the newborn has been reported with SSRI exposure; although the absolute risk is small, monitoring of infants exposed to SSRIs late in pregnancy is recommended (Masarwa 2019; Ng 2019). The long-term effects of in utero SSRI exposure on infant neurodevelopment and behavior are not known (CANMAT [MacQueen 2016]).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of paroxetine may be altered. The maternal CYP2D6 genotype also influences if paroxetine plasma concentrations increase or decrease during pregnancy (Hostetter 2000; Ververs 2009; Westin 2017). A case report describes symptoms of antidepressant discontinuation syndrome (night sweats, nightmares) in a patient during the first trimester of pregnancy, requiring a continued increase of her paroxetine dose as pregnancy progressed for resolution. The patient was found to be an extensive metabolizer of CYP2D6 (Javelot 2020). Close clinical monitoring as pregnancy progresses and therapeutic drug monitoring to detect patterns of changing plasma concentrations is recommended to assist dose adjustment when needed; CYP2D6 genotyping may also be considered (Schoretsanitis 2020).</p>
<p style="text-indent:0em;margin-top:2em;">If treatment is initiated for the first time during pregnancy, paroxetine is not recommended (CANMAT [MacQueen 2016]; Larsen 2015; WFSBP [Bauer 2013]). The American College of Obstetricians and Gynecologists also recommends that therapy with paroxetine be avoided during pregnancy, if possible, and that fetuses exposed in early pregnancy be assessed with a fetal echocardiography (ACOG 2008). If pregnancy occurs during paroxetine therapy, treatment should be changed, except in extraordinary circumstances (Larsen 2015). Untreated or inadequately treated psychiatric illness may lead to poor adherence with prenatal care and adverse pregnancy outcomes. Therapy with antidepressants during pregnancy should be individualized; treatment with antidepressant medication is recommended for pregnant patients with severe major depressive disorder (ACOG 2008; CANMAT [MacQueen 2016]). Patients treated for major depression and who are euthymic prior to pregnancy are more likely to experience a relapse when medication is discontinued (68%) as compared to pregnant patients who continue taking antidepressant medications (26%) (Cohen 2006).</p>
<p style="text-indent:0em;margin-top:2em;">Menopausal vasomotor symptoms do not occur during pregnancy; therefore, the use of paroxetine for the treatment of menopausal vasomotor symptoms is contraindicated in pregnant patients.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to antidepressant medications is ongoing. Patients exposed to antidepressants during pregnancy are encouraged to enroll in the National Pregnancy Registry for Antidepressants. Pregnant patients 18 to 45 years of age or their health care providers may contact the registry to enroll; enrollment should be done as early in pregnancy as possible (1-866-961-2388 or https://womensmentalhealth.org/research/pregnancyregistry/antidepressants/).</p></div>
<div class="block mopp drugH1Div" id="F53568210"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure, heart rate, liver and renal function, serum sodium in at-risk populations (as clinically indicated). Monitor patient periodically for symptom resolution; monitor for worsening depression, suicidality, and associated behaviors (especially at the beginning of therapy or when doses are increased or decreased); signs and symptoms of serotonin syndrome; akathisia.</p></div>
<div class="block pha drugH1Div" id="F206554"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Paroxetine is a selective serotonin reuptake inhibitor, chemically unrelated to tricyclic, tetracyclic, or other antidepressants; presumably, the inhibition of serotonin reuptake from brain synapse stimulated serotonin activity in the brain</p></div>
<div class="block phk drugH1Div" id="F206573"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Anxiety disorders (generalized anxiety, obsessive-compulsive, panic, and posttraumatic stress disorder): Initial effects may be observed within 2 weeks of treatment, with continued improvements through 4 to 6 weeks (Issari 2016; Varigonda 2016; WFSBP [Bandelow 2023a]); some experts suggest up to 12 weeks of treatment may be necessary for response, particularly in patients with obsessive-compulsive disorder and posttraumatic stress disorder (BAP [Baldwin 2014]; Katzman 2014; WFSBP [Bandelow 2023a]; WFSBP [Bandelow 2023b]).</p>
<p style="text-indent:-2em;margin-left:4em;">Body dysmorphic disorder: Initial effects may be observed within 2 weeks; some experts suggest up to 12 to 16 weeks of treatment may be necessary for response in some patients (Phillips 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Depression: Initial effects may be observed within 1 to 2 weeks of treatment, with continued improvements through 4 to 6 weeks (Papakostas 2006; Posternak 2005; Szegedi 2009; Taylor 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">Premenstrual dysphoric disorder: Initial effects may be observed within the first few days of treatment, with response at the first menstrual cycle of treatment (ISPMD [Nevatte 2013]).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Completely absorbed following oral administration</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 8.7 L/kg (3 to 28 L/kg)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 93% to 95%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic via CYP2D6 enzymes; primary metabolites are formed via oxidation and methylation of parent drug, with subsequent glucuronide/sulfate conjugation; nonlinear pharmacokinetics (via 2D6 saturation) may be seen with higher doses and longer duration of therapy. Metabolites exhibit ~2% potency of parent compound. C<sub>min</sub> concentrations are 70% to 80% greater in the elderly compared to nonelderly patients; clearance is also decreased.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Immediate release tablet and oral suspension have equal bioavailability</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Paxil: 21 hours; Paxil CR: 15 to 20 hours; Pexeva: 33.2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">Capsules: Median: 6 hours (range: 3 to 8 hours)</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets, oral suspension: Immediate release: Mean: 5.2 to 8.1 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets: Controlled release: 6 to 10 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (64%, 2% as unchanged drug); feces (36% primarily via bile, &lt;1% as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51192058"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: AUC increased approximately 3.5 times with CrCl &lt;30 mL/minute. AUC increased 2-fold with CrCl 30 to 60 mL/minute (Doyle 1989).</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: 2-fold increase in plasma concentrations and AUC after 14 days of daily administration in patients with alcohol-related cirrhosis (Dalhoff 1991).</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Minimum concentrations were 70% to 80% greater than in younger patients. Reduce initial dosage; no dosage adjustment is necessary with Brisdelle.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F206580"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Paxitab | Seroxat</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Ginstar | Meplar | Neurotrox | Olane xr | Paroxetina cevallos | Paroxetina lepret | Paroxetina Teva | Paxil | Psicoasten | Sicotral | Tiarix | Tioari | Xilanic</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Allenopar | Ennos | Paluxetil | Parocetan | Paroxat | Paroxetin +pharma | Paroxetin actavis | Paroxetin Alternova | Paroxetin arcana | Paroxetin easypharm | Paroxetin Genericon | Paroxetin interpharm | Paroxetin Merckle | Paroxetin pfizer | Paroxetin Ratiopharm | Paroxetin ratiopharm GmbH | Paroxetin Sandoz | Paroxetin-1a pharma gmbh | Seroxat</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo paroxetine | Aropax | Cm paroxetine | Extine | Genrx paroxetine | Oxetine | Paroxetine | Paroxetine Actavis | Paroxetine an | Paroxetine Generic Health | Paroxetine pfizer | Paroxetine sandoz | Paroxetine synthon | Paroxetine Winthrop | Paroxetine-Ga | Paxtine | Pharmacor Paroxetine | Pharmacor Paroxo | Roxet | Tw paroxetine</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Melev | Oxat | Panirid | Parotin | Paroxet</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Aropax | Paroxetin actavis | Paroxetine ab | Paroxetine bexal | Paroxetine eg | Paroxetine eurogenerics | Paroxetine merck-generics | Paroxetine pfizer | Paroxetine ratiopharm | Paroxetine sandoz | Paroxetine teva | Paroxetine topgen | Paroxiteva | Seroxat</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Deroxat</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Depoxat | Parix | Paroxat | Paroxetine | Rexetin | Seroxat | Xetanor</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Aropax | Arotin | Benepax | Cebrilin | Cloridrato de paroxetina | Moratus | Parox | Paroxiliv | Paxil | Paxil cr | Paxtrat | Pondera | Pondera xr | Pondix | Praxetina | Roxetin | Roxetin xr | Sertero | Zyparox</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Deroxat | Parexat | Paronex | Paroxetin - 1 A Pharma | Paroxetin actavis | Paroxetin mepha | Paroxetin spirig | Paroxetin Spirig HC | Paroxetin zentiva</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Arotex | Aroxat | Bectam | Deroxat | Pamax | Parodox | Seretran | Traviata</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Le you | Sai le te | Seroxat | Shu tan luo</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Nath | Pacex | Paroxetina | Paxan | Seropax | Seroxat</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo parox | Arketis | Parolex | Paroxetin | Paroxetin +pharma | Paroxetin aurovitas | Paroxetin Orion | Paroxetin teva | Paroxinor | Remood | Seroxat</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Euplix | Oxet | Parolich | Parox | Paroxalon | Paroxat | Paroxedura | Paroxetin | Paroxetin 1a pharma | Paroxetin actavis | Paroxetin AL | Paroxetin aurobindo | Paroxetin Basics | Paroxetin Beta | Paroxetin CT | Paroxetin Heumann | Paroxetin Holsten | Paroxetin Hormosan | Paroxetin Isis | Paroxetin neuraxpharm | Paroxetin Ratiopharm | Paroxetin Real | Paroxetin Sandoz | Paroxetin Stada | Paroxetin teva | Seroxat | Tagonis</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Paroxetin 1a farma | Paroxetin genthon | Paroxetin nm | Paroxetin pcd | Paroxetin Ratiopharm</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Europaroxet | Laparox | Meplar | Paroxet | Paroxetina | Paxil | Prexor | Traviata</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Paroten | Paroxetina | Paxil | Pondera | Seretran | Seretran CR | Xerenex</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Arketis | Paroxat | Paroxetin hexal | Paroxetin nycomed | Paroxetine Orion | Rexetin | Seroxat</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Depanx | Paroxedep cr | Paroxedur | Paroxetine | Paxetin | Seroxat | Xandol</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Arapaxel | Frosinor | Motivan | Paroxetina | Paroxetina almus | Paroxetina alter | Paroxetina angenerico | Paroxetina aphar | Paroxetina Apotex | Paroxetina Arafarma group | Paroxetina aurobindo | Paroxetina aurovitas | Paroxetina bayvit | Paroxetina bexal | Paroxetina bluepharma | Paroxetina cinfa | Paroxetina Combix | Paroxetina Curaxys | Paroxetina cuve | Paroxetina davur | Paroxetina Edigen | Paroxetina kern | Paroxetina Mabo | Paroxetina merck | Paroxetina mundogen | Paroxetina Normon | Paroxetina pensa | Paroxetina pharma combix | Paroxetina Pharmacia | Paroxetina pharmagenus | Paroxetina Qualigen | Paroxetina ranbaxy | Paroxetina rimafar | Paroxetina sandoz | Paroxetina stada | Paroxetina tarbis | Paroxetina Teva | Paroxetina vir | Paroxetina Winthrop | Seroxat | Xetin</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Seroxat</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Optipar | Paroksetiini glaxo | Paroxetin actavis | Paroxetin Alpharma | Paroxetin avansor | Paroxetin Copyfarm | Paroxetin generics | Paroxetin Orion | Paroxetin pfizer | Paroxetin ratiopharma | Paroxetin Sandoz | Paroxetin Stada | Seroxat</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Deroxat | Divarius | Paroxetine Actavis | Paroxetine Alter | Paroxetine Arrow | Paroxetine cristers | Paroxetine eg | Paroxetine evolugen | Paroxetine g gam | Paroxetine irex | Paroxetine Isomed | Paroxetine merck | Paroxetine pfizer | Paroxetine phr lab | Paroxetine Qualimed | Paroxetine ratiopharm | Paroxetine RPG | Paroxetine sandoz | Paroxetine Zydus</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Paroxetine | Paroxetine cox | Paroxetine kent | Paroxetine pfizer | Paroxetine sandoz | Seroxat</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Noprilex | Parolet | Parosat | Paroxetine | Paroxetine/mylan | Paroxetine/teva | Paroxia | Seroxat | Solben</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo paroxetine | Parotin | Seroxat</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Deprozel | Paluxon | Paroksetin PharmaS | Paroxin | Seroxat</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Apodepi | Paretin | Parogen | Paroxat | Paroxetin pfizer | Paroxetin Ratiopharm | Rexetin | Seroxat | Xetanor</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Seroxat</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Meloxat | Paroser | Parox | Paxt | Seroxat</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Paroxetine teva | Paxxet | Seroxat</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Anxifree p | Aroximat cr | Cnpaxet | Depaxil | Emoxet | Fordep | Nobix | Obsikon CR | Oxitine cr | Panex | Paradise XR | Pardep | Pari | Pari cr | Paro 40 | Paro cr | Parogen cr | Parolyst | Paronet cr | Parotin | Paroxee | Paroxet | Patinex | Patroxta | Paxgem xr | Paxidep-cr | Paxiford cr | Paxiniche cr | Paxinta cr | Paxit | Paxonil | Petin | Pexep | Pexep cr | Praxet CR | Praxo | Praxohenz cr | Pxn | Qxt | Raxit | Serotin | Xepar | Xet | Xet cr | Xl-paro | Xodep</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Daparox | Eutimil | Paroxetina | Paroxetina actavis | Paroxetina Almu | Paroxetina aurobindo | Paroxetina doc generici | Paroxetina eg | Paroxetina Ge | Paroxetina pensa | Paroxetina sandoz | Paroxetina zentiva | Sereupin | Seroxat</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Paxitab | Seroxat | Unirox</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Paroxetine | Paroxetine aspen | Paroxetine dk | Paroxetine ffp | Paroxetine jg | Paroxetine Nissin | Paroxetine Towa | Paxil</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Adco paroxetine | Pyrantin | Seroxat</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">A Xat | A xat cr | Paroctin | Parosenin | Parox | Parox cr | Paroxat cr | Paroxen | Paroxetine | Paroxil | Parozat | Paxerontine sr | Paxetil | Paxil | Paxil cr | Pharma paroxetine | Sandoz paroxetine | Seroksetin | Seroxart | Seroxat | Wi paroxetine | Yungjin paroxetine cr</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Paxitab | Seroxat</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo paroxetine | Parlotin | Paroxat | Paxera | Paxil | Paxitab | Pms-paroxetine | Seroxat | Unirox</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Arketis | Paroxetin hexal | Paroxetin Orion | Paroxetine Actavis | Paroxetine aurobindo | Seroxat</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Aropax | Paroxetine apotex | Paroxetine eg | Paroxetine ratiopharm | Seroxat</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Arketis | Paroxetin | Paroxetin actavis | Paroxetin aurobindo | Paroxetin nycomed | Paroxetin Orion | Rexetin | Seroxat</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Deroxat | Divarius | Panekal | Paroxetine | Paroxetine win | Tre zen | Xerium</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Andepa | Anziatina | Apo oxpar | Aropax | Aropax CR | Bioserox | Chipten | Collepax | Cronadyn | Daboxanil | Davol | Ixicrol | Lysande | Ocampina | Ontracel | Paroxetina | Paxil | Paxil cr | Riedilex | Tamcere | Umesalil | Xerenex | Xetroran</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo paroxetine | Seroxat</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Mizetin | Paroxetine sandoz | Seroxat</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Deroxat | Paroxetine | Paroxetine Actavis | Paroxetine Alpharma O.F. | Paroxetine cf | Paroxetine HCL | Paroxetine hcl-anhydraat A | Paroxetine merck | Paroxetine prolepha | Paroxetine sandoz | Seroxat</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Paroxat | Paroxetin | Paroxetin aristo | Paroxetin aurobindo | Paroxetin gea | Paroxetin GlaxoSmithKline | Paroxetin hexal | Paroxetin nycomed | Paroxetin pfizer | Paroxetin Sandoz | Seroxat</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo paroxetine | Aropax | Loxamine | Paxtine</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Paroxet | Paroxetina | Paxil | Seroxat | Sindep | Xerenex</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Seroxat | Xet</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Aeva | Auroprox | Brisdel | Depexil cr | Depin | Deroxat | Dexet plus | Exatine cr | Excite cr | Fyprox | Gerox | Gerox cr | Harmony | Hiprox | Impika | Impika cr | Invika CR | Jurox cr | Karox | Neoxetine | Ob parox | Obexil | Olixat cr | P ox | Panox cr | Paraice | Paraxyl | Paraxyl CR | Pari | Pari cr | Parinom | Parinom cr | Pariva | Pariz | Paromax | Paromax cr | Paronex | Paronex cr | Parotin | Parox Q | Paroxil | Paroxin | Paroxin cr | Paroxitol | Paroxiwel cr | Paroxywin cr | Parxet | Pax cr | Paxet | Paxetin | Perison cr | Peroxa | Peroxa cr | Peroxit | Pexeva | Pexot | Pexot cr | Pext cr | Pexta | Plasare | Praxlet | Praxlet cr | Prixteen | Prixteen cr | Progra | Proksitin | Pronitron | Quixet | Rapox | Raxil cr | Roxetine | Roxetine cr | Sadgon | Seroless | Seroxat | Zepid</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Parogen | Paroxetine aurobindo | Paroxetine aurovitas | Paroxinor | Paxtin | Rexetin | Seroxat</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Brisdelle | Paroxetine | Paroxetine extended release | Paroxetine HCL | Paxil | Pexeva</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Denerval | Oxepar | Paroxetina | Paroxetina almus | Paroxetina aurobindo | Paroxetina aurovitas | Paroxetina generis | Paroxetina limeg | Paroxetina Pfizer | Paroxetina sandoz | Paroxetina tedec | Paroxetina Teva | Paxetil | Paxpar | Seroxat | Voltak | Zanoxina</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Aropax | Openlix | Paroxetina pasteur | Sicotropin | Tiarix</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Paroxat | Paxitab | Seroxat | Seroxat CR | Unirox</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Als paroxetin | Arketis | Paroxetin teva | Rexetin | Seroxat</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Actaparoxetine | Apo paroxetine | Paroxetine | Paxil | Plisil | Plisil n | Rexetin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo paroxetine | Axor | Pado | Paroxat | Paxitab | Pms-paroxetine | Seroxat</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Arketis | Euplix | Paroxetin | Paroxetin actavis | Paroxetin Alpharma | Paroxetin Amneal | Paroxetin aurobindo | Paroxetin Copyfarm | Paroxetin ebb | Paroxetin Eql Pharma | Paroxetin gea | Paroxetin hexal | Paroxetin Mylan | Paroxetin Orion | Paroxetin Ratiopharm | Paroxetin Sandoz | Paroxetin teva | Paroxiflex | Paroxistad | Seroxat</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo paroxetine | Seroxat</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Paluxon | Paroksetin Actavis | Plisil | Seroxat</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Arketis | Paretin | Parolex | Paroxetin | Paroxetin +pharma | Paroxetin Orion | Paroxetin teva | Remood | Seroxat</span>;</li>
<li>
<span class="countryCode">(SY)</span> <span class="country">Syrian Arab Republic</span><span class="countrySeparator">: </span><span class="drugName">Depretin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Seroxat</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Deproxyl | Deroxat | Divarius | Parexat | Paroxine | Paxetin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Paroteva | Paxera | Paxil | Paxotin | Seroxat</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Apo paroxetine | Caremod | Eugine | Paroxe | Seroxat | Setine | Xet | Xetine-P</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Luxotil | Paroxin | Paxil | Rexetin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Blifedan | Efil | Meplar | Parotina | Paroxet | Paxelle | Prexetin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Parexel | Parotin | Paroxetina | Paroxetina bluepharma | Paxil | Prismarox</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Sumiko</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adco paroxetine | Aropax | Deparoc | Hexal paroxetine | Lenio | Paroxetine Unicorn | Zydus Paroxetine</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Aropax | Pari cr</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Aropax</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7887764">
<a name="7887764"></a>Ahmad S. Paroxetine-induced priapism. <i>Arch Intern Med</i>. 1995;155(6):645.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/7887764/pubmed" id="7887764" target="_blank">7887764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18535650">
<a name="18535650"></a>Ahmed R, Eagleton C. Toxic epidermal necrolysis after paroxetine treatment. <i>N Z Med J</i>. 2008;121(1274):86-89.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/18535650/pubmed" id="18535650" target="_blank">18535650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25356302">
<a name="25356302"></a>Althof SE, McMahon CG, Waldinger MD, et al. An update of the International Society of Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE). <i>Sex Med</i>. 2014;2(2):60-90. doi:10.1002/sm2.28<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/25356302/pubmed" id="25356302" target="_blank">25356302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. <i>Obstet Gynecol.</i> 2008;111(4):1001-1020. doi:10.1097/AOG.0b013e31816fd910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.2010">
<a name="APA.2010"></a>American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Published October 2010. Accessed June 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.1">
<a name="APA.1"></a>American Psychological Association (APA). Clinical practice guideline for the treatment of depression across three age cohorts. https://www.apa.org/depression-guideline/guideline.pdf. Published February 16, 2019. Accessed April 21, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32777011">
<a name="32777011"></a>Anderson KN, Lind JN, Simeone RM, et al. Maternal use of specific antidepressant medications during early pregnancy and the risk of selected birth defects. <i>JAMA Psychiatry</i>. 2020;77(12):1246-1255. doi:10.1001/jamapsychiatry.2020.2453<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/32777011/pubmed" id="32777011" target="_blank">32777011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21190637">
<a name="21190637"></a>Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. <i>J Clin Psychiatry</i>. 2010;71(12):1565-1575. doi:10.4088/JCP.09r05786blu<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/21190637/pubmed" id="21190637" target="_blank">21190637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9518913">
<a name="9518913"></a>Andrews C, Pinner G. Postural hypotension induced by paroxetine. <i>BMJ</i>. 1998;316(7131):595. doi:10.1136/bmj.316.7131.595<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/9518913/pubmed" id="9518913" target="_blank">9518913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24777151">
<a name="24777151"></a>Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. <i>Am J Gastroenterol</i>. 2014;109(6):811-819. doi:10.1038/ajg.2014.82<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/24777151/pubmed" id="24777151" target="_blank">24777151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12107856">
<a name="12107856"></a>Azaz-Livshits T, Hershko A, Ben-Chetrit E. Paroxetine associated hepatotoxicity: a report of 3 cases and a review of the literature. <i>Pharmacopsychiatry</i>. 2002;35(3):112-115. doi:10.1055/s-2002-31515<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/12107856/pubmed" id="12107856" target="_blank">12107856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8654061">
<a name="8654061"></a>Baldassano CF, Truman CJ, Nierenberg A, Ghaemi SN, Sachs GS. Akathisia: a review and case report following paroxetine treatment. <i>Compr Psychiatry</i>. 1996;37(2):122-124. doi:10.1016/s0010-440x(96)90572-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/8654061/pubmed" id="8654061" target="_blank">8654061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23219059">
<a name="23219059"></a>Baldessarini RJ, Faedda GL, Offidani E, et al. Antidepressant-associated mood-switching and transition from unipolar major depression to bipolar disorder: a review. <i>J Affect Disord</i>. 2013;148(1):129-135. doi:10.1016/j.jad.2012.10.033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/23219059/pubmed" id="23219059" target="_blank">23219059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10627793">
<a name="10627793"></a>Baldwin D, Bobes J, Stein DJ, Scharwächter I, Faure M. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. <i>Br J Psychiatry</i>. 1999;175:120-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/10627793/pubmed" id="10627793" target="_blank">10627793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24713617">
<a name="24713617"></a>Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.<i> J Psychopharmacol</i>. 2014;28(5):403-439. doi:10.1177/0269881114525674<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/24713617/pubmed" id="24713617" target="_blank">24713617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900161">
<a name="35900161"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part I: anxiety disorders. <i>World J Biol Psychiatry</i>. 2023a;24(2):79-117. doi:10.1080/15622975.2022.2086295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/35900161/pubmed" id="35900161" target="_blank">35900161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900217">
<a name="35900217"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part II: OCD and PTSD. <i>World J Biol Psychiatry</i>. 2023b;24(2):118-134. doi:10.1080/15622975.2022.2086296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/35900217/pubmed" id="35900217" target="_blank">35900217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22540422">
<a name="22540422"></a>Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J; WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. <i>Int J Psychiatry Clin Pract. </i>2012;16(2):77-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/22540422/pubmed" id="22540422" target="_blank">22540422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28148614">
<a name="28148614"></a>Bartlett D. Drug-induced serotonin syndrome. <i>Crit Care Nurse</i>. 2017;37(1):49-54. doi:10.4037/ccn2017169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/28148614/pubmed" id="28148614" target="_blank">28148614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23879318">
<a name="23879318"></a>Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller HJ; World Federation of Societies of Biological Psychiatry Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. <i>World J Biol Psychiatry</i>. 2013;14(5):334-385.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/23879318/pubmed" id="23879318" target="_blank">23879318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25677972">
<a name="25677972"></a>Bauer M, Severus E, Köhler S, Whybrow PC, Angst J, Möller HJ; WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder-update 2015. <i>World J Biol Psychiatry</i>. 2015;16(2):76-95. doi: 10.3109/15622975.2014.1001786.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/25677972/pubmed" id="25677972" target="_blank">25677972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12479080">
<a name="12479080"></a>Bauer M, Whybrow PC, Anst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. <i>World J Biol Psychiatry</i>. 2002;3(2):69-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/12479080/pubmed" id="12479080" target="_blank">12479080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9161313">
<a name="9161313"></a>Benbow SJ, Gill G. Paroxetine and hepatotoxicity. <i>BMJ</i>. 1997;314(7091):1387. doi:10.1136/bmj.314.7091.1387a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/9161313/pubmed" id="9161313" target="_blank">9161313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22299006">
<a name="22299006"></a>Berle JO, Spigset O. Antidepressant use during breastfeeding. <i>Curr Womens Health Rev</i>. 2011;7(1):28-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/22299006/pubmed" id="22299006" target="_blank">22299006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32135392">
<a name="32135392"></a>Biffi A, Cantarutti A, Rea F, Locatelli A, Zanini R, Corrao G. Use of antidepressants during pregnancy and neonatal outcomes: an umbrella review of meta-analyses of observational studies. <i>J Psychiatr Res</i>. 2020;124:99-108. doi:10.1016/j.jpsychires.2020.02.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/32135392/pubmed" id="32135392" target="_blank">32135392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21893349">
<a name="21893349"></a>Bismuth-Evenzal Y, Gonopolsky Y, Gurwitz D, Iancu I, Weizman A, Rehavi M. Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs. <i>J Affect Disord</i>. 2012;136(1-2):99-103. doi:10.1016/j.jad.2011.08.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/21893349/pubmed" id="21893349" target="_blank">21893349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30081645">
<a name="30081645"></a>Bixby AL, VandenBerg A, Bostwick JR. Clinical management of bleeding risk with antidepressants. <i>Ann Pharmacother</i>. 2019;53(2):186-194. doi:10.1177/1060028018794005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/30081645/pubmed" id="30081645" target="_blank">30081645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29306047">
<a name="29306047"></a>Boisseau CL, Rasmussen SA. Unified protocol for the discontinuation of long-term serotonin reuptake inhibitors in obsessive compulsive disorder: Study protocol and methods. <i>Contemp Clin Trials</i>. 2018;65:157-163.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/29306047/pubmed" id="29306047" target="_blank">29306047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17581442">
<a name="17581442"></a>Bonnot O, Warot D, Cohen D. Priapism associated with sertraline. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(7):790-791. doi:10.1097/chi.0b013e318067da56<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/17581442/pubmed" id="17581442" target="_blank">17581442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15784664">
<a name="15784664"></a>Boyer EW, Shannon M. The serotonin syndrome. <i>N Engl J Med</i>. 2005;352(11):1112-20. doi: 10.1056/NEJMra041867. Erratum in: <i>N Engl J Med</i>. 2007;356(23):2437. Erratum in: <i>N Engl J Med</i>. 2009;361(17):1714.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/15784664/pubmed" id="15784664" target="_blank">15784664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brisdelle.2">
<a name="Brisdelle.2"></a>Brisdelle (paroxetine) [prescribing information]. Roswell, GA: Sebela Pharmaceuticals Inc; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brisdelle.1">
<a name="Brisdelle.1"></a>Brisdelle (paroxetine) [prescribing information]. Roswell, GA: Sebela Pharmaceuticals Inc; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27508501">
<a name="27508501"></a>Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. <i>Psychother Psychosom</i>. 2016;85(5):270-288. doi:10.1159/000447034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/27508501/pubmed" id="27508501" target="_blank">27508501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Casper.2020">
<a name="Casper.2020"></a>Casper RF, Yonkers KA. Treatment of premenstrual syndrome and premenstrual dysphoric disorder. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 11, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27135704">
<a name="27135704"></a>Chen HY, Lin CL, Lai SW, Kao CH. Association of selective serotonin reuptake inhibitor use and acute angle-closure glaucoma. <i>J Clin Psychiatry</i>. 2016;77(6):e692-e696. doi:10.4088/JCP.15m10038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/27135704/pubmed" id="27135704" target="_blank">27135704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29483201">
<a name="29483201"></a>Cheung AH, Zuckerbrot RA, Jensen PS, Laraque D, Stein REK; GLAD-PC Steering Group. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part II. Treatment and ongoing management. <i>Pediatrics</i>. 2018;141(3):e20174082. doi:10.1542/peds.2017-4082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/29483201/pubmed" id="29483201" target="_blank">29483201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16449615">
<a name="16449615"></a>Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. <i>JAMA</i>. 2006;295(5):499-507. doi:10.1001/jama.295.5.499<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/16449615/pubmed" id="16449615" target="_blank">16449615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15963219">
<a name="15963219"></a>Colakoglu O, Tankurt E, Unsal B, et al. Toxic hepatitis associated with paroxetine. <i>Int J Clin Pract</i>. 2005;59(7):861-862. doi:10.1111/j.1368-5031.2005.00572.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/15963219/pubmed" id="15963219" target="_blank">15963219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29463440">
<a name="29463440"></a>Coskuner ER, Culha MG, Ozkan B, Kaleagasi EO. Post-SSRI sexual dysfunction: preclinical to clinical. Is it fact or fiction? <i>Sex Med Rev</i>. 2018;6(2):217-223. doi:10.1016/j.sxmr.2017.11.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/29463440/pubmed" id="29463440" target="_blank">29463440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19587851">
<a name="19587851"></a>Costagliola C, Parmeggiani F, Semeraro F, Sebastiani A. Selective serotonin reuptake inhibitors: a review of its effects on intraocular pressure. <i>Curr Neuropharmacol</i>. 2008;6(4):293-310. doi:10.2174/157015908787386104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/19587851/pubmed" id="19587851" target="_blank">19587851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19716436">
<a name="19716436"></a>Dall M, Schaffalitzky de Muckadell OB, Lassen AT, Hansen JM, Hallas J. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. <i>Clin Gastroenterol Hepatol</i>. 2009;7(12):1314-1321. doi:10.1016/j.cgh.2009.08.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/19716436/pubmed" id="19716436" target="_blank">19716436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1839532">
<a name="1839532"></a>Dalhoff K, Almdal TP, Bjerrum K, Keiding S, Mengel H, Lund J. Pharmacokinetics of paroxetine in patients with cirrhosis. <i>Eur J Clin Pharmacol</i>. 1991;41(4):351-354. doi:10.1007/BF00314966<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/1839532/pubmed" id="1839532" target="_blank">1839532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25262043">
<a name="25262043"></a>De Picker L, Van Den Eede F, Dumont G, Moorkens G, Sabbe BG. Antidepressants and the risk of hyponatremia: a class-by-class review of literature. <i>Psychosomatics</i>. 2014;55(6):536-547. doi:10.1016/j.psym.2014.01.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/25262043/pubmed" id="25262043" target="_blank">25262043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10665639">
<a name="10665639"></a>Deisenhammer EA, Trawöger R. Penile anesthesia associated with sertraline use. <i>J Clin Psychiatry</i>. 1999;60(12):869-870. doi:10.4088/jcp.v60n1218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/10665639/pubmed" id="10665639" target="_blank">10665639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14566199">
<a name="14566199"></a>DeVane CL. Pharmacokinetics, drug interactions, and tolerability of paroxetine and paroxetine CR. <i>Psychopharmacol Bull</i>. 2003;37(suppl 1):S29-S41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/14566199/pubmed" id="14566199" target="_blank">14566199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Diler.1">
<a name="Diler.1"></a>Diler RS, Avci A. Selective serotonin reuptake inhibitor discontinuation syndrome in children: Six case reports. <i>Current Therapeutic Research.</i> 2002;63(3):188-197.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16434782">
<a name="16434782"></a>Dopheide JA. Recognizing and treating depression in children and adolescents. <i>Am J Health Syst Pharm</i>. 2006;63(3):233-243. doi:10.2146/ajhp050264<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/16434782/pubmed" id="16434782" target="_blank">16434782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29536379">
<a name="29536379"></a>Douros A, Ades M, Renoux C. Risk of intracranial hemorrhage associated with the use of antidepressants inhibiting serotonin reuptake: a systematic review. <i>CNS Drugs</i>. 2018;32(4):321-334. doi:10.1007/s40263-018-0507-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/29536379/pubmed" id="29536379" target="_blank">29536379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2530798">
<a name="2530798"></a>Doyle GD, Laher M, Kelly JG, et al. The pharmacokinetics of paroxetine in renal impairment. <i>Acta Psychiatr Scand Suppl</i>. 1989;350:89-90. doi:10.1111/j.1600-0447.1989.tb07181.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/2530798/pubmed" id="2530798" target="_blank">2530798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12925718">
<a name="12925718"></a>Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: Simple and accurate diagnostic decision rules for serotonin toxicity. <i>QJM</i>. 2003;96(9):635-642. doi:10.1093/qjmed/hcg109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/12925718/pubmed" id="12925718" target="_blank">12925718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9161312">
<a name="9161312"></a>Eke T, Bates AK. Acute angle closure glaucoma associated with paroxetine. <i>BMJ</i>. 1997;314(7091):1387. doi:10.1136/bmj.314.7091.1387<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/9161312/pubmed" id="9161312" target="_blank">9161312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24631758">
<a name="24631758"></a>Erie JC, Brue SM, Chamberlain AM, Hodge DO. Selective serotonin reuptake inhibitor use and increased risk of cataract surgery: a population-based, case-control study. <i>Am J Ophthalmol</i>. 2014;158(1):192-197.e1. doi:10.1016/j.ajo.2014.03.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/24631758/pubmed" id="24631758" target="_blank">24631758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20207418">
<a name="20207418"></a>Etminan M, Mikelberg FS, Brophy JM. Selective serotonin reuptake inhibitors and the risk of cataracts: a nested case-control study. <i>Ophthalmology</i>. 2010;117(6):1251-1255. doi:10.1016/j.ophtha.2009.11.042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/20207418/pubmed" id="20207418" target="_blank">20207418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27284122">
<a name="27284122"></a>Evrensel A, Önen Ünsalver B, Akyol A, Ceylan ME. A case of galactorrhea during paroxetine treatment. <i>Int J Psychiatry Med</i>. 2016;51(3):302-305. doi:10.1177/0091217416651257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/27284122/pubmed" id="27284122" target="_blank">27284122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25721705">
<a name="25721705"></a>Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. <i>Psychother Psychosom</i>. 2015;84(2):72-81. doi:10.1159/000370338<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/25721705/pubmed" id="25721705" target="_blank">25721705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26554283">
<a name="26554283"></a>Fenske JN, Petersen K. Obsessive-compulsive disorder: diagnosis and management. <i>Am Fam Physician</i>. 2015;92(10):896-903.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/26554283/pubmed" id="26554283" target="_blank">26554283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19621834">
<a name="19621834"></a>Fenske JN, Schwenk TL. Obsessive compulsive disorder: diagnosis and management. <i>Am Fam Physician</i>. 2009;80(3):239-245.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/19621834/pubmed" id="19621834" target="_blank">19621834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31648376">
<a name="31648376"></a>Fitton CA, Steiner MFC, Aucott L, et al. In utero exposure to antidepressant medication and neonatal and child outcomes: a systematic review. <i>Acta Psychiatr Scand</i>. 2020;141(1):21-33. doi:10.1111/acps.13120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/31648376/pubmed" id="31648376" target="_blank">31648376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17485726">
<a name="17485726"></a>Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. <i>N Engl J Med</i>. 2007;356(23):2343-2346. doi:10.1056/NEJMp078015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/17485726/pubmed" id="17485726" target="_blank">17485726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27773479">
<a name="27773479"></a>Gandhi S, Shariff SZ, Al-Jaishi A, et al. Second-generation antidepressants and hyponatremia risk: a population-based cohort study of older adults. <i>Am J Kidney Dis</i>. 2017;69(1):87-96. doi:10.1053/j.ajkd.2016.08.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/27773479/pubmed" id="27773479" target="_blank">27773479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15502598">
<a name="15502598"></a>Geller DA, Wagner KD, Emslie G, et al. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: A randomized, multicenter, double-blind, placebo-controlled trial. <i>J Am Acad Child Adolesc Psychiatry.</i> 2004;43(11):1387-1396.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/15502598/pubmed" id="15502598" target="_blank">15502598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32215771">
<a name="32215771"></a>Gill N, Bayes A, Parker G. A review of antidepressant-associated hypomania in those diagnosed with unipolar depression-risk factors, conceptual models, and management. <i>Curr Psychiatry Rep</i>. 2020;22(4):20. doi:10.1007/s11920-020-01143-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/32215771/pubmed" id="32215771" target="_blank">32215771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10855465">
<a name="10855465"></a>González E, Minguez L, Sanguino RM. Galactorrhea after paroxetine treatment. <i>Pharmacopsychiatry</i>. 2000;33(3):118. doi:10.1055/s-2000-7979<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/10855465/pubmed" id="10855465" target="_blank">10855465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22193145">
<a name="22193145"></a>Goodman NF, Cobin RH, Ginzburg SB, Katz IA, Wood DE; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause: executive summary of recommendations. <i>Endocr Pract</i>. 2011;17(6):949-954.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/22193145/pubmed" id="22193145" target="_blank">22193145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12243609">
<a name="12243609"></a>Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. <i>Ann Pharmacother</i>. 2002;36(10):1577-1589. doi:10.1345/aph.1A195<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/12243609/pubmed" id="12243609" target="_blank">12243609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29522259">
<a name="29522259"></a>Grzeskowiak LE, Leggett C, Costi L, Roberts CT, Amir LH. Impact of serotonin reuptake inhibitor use on breast milk supply in mothers of preterm infants: a retrospective cohort study. <i>Br J Clin Pharmacol</i>. 2018;84(6):1373-1379. doi:10.1111/bcp.13575<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/29522259/pubmed" id="29522259" target="_blank">29522259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11347722">
<a name="11347722"></a>Haddad PM. Antidepressant discontinuation syndromes. <i>Drug Saf</i>. 2001;24(3):183-197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/11347722/pubmed" id="11347722" target="_blank">11347722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17506225">
<a name="17506225"></a>Halperin D, Reber G. Influence of antidepressants on hemostasis. <i>Dialogues Clin Neurosci</i>. 2007;9(1):47-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/17506225/pubmed" id="17506225" target="_blank">17506225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16520440">
<a name="16520440"></a>Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. <i>Arch Gen Psychiatry</i>. 2006;63(3):332-339. doi:10.1001/archpsyc.63.3.332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/16520440/pubmed" id="16520440" target="_blank">16520440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29337001">
<a name="29337001"></a>Hathaway EE, Walkup JT, Strawn JR. Antidepressant treatment duration in pediatric depressive and anxiety disorders: How long is long enough? <i>Curr Probl Pediatr Adolesc Health Care</i>. 2018;48(2):31-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/29337001/pubmed" id="29337001" target="_blank">29337001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28577352">
<a name="28577352"></a>Heller HM, Ravelli ACJ, Bruning AHL, et al. Increased postpartum haemorrhage, the possible relation with serotonergic and other psychopharmacological drugs: a matched cohort study. <i>BMC Pregnancy Childbirth</i>. 2017;17(1):166. doi:10.1186/s12884-017-1334-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/28577352/pubmed" id="28577352" target="_blank">28577352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12727706">
<a name="12727706"></a>Hendrick V, Stowe ZN, Altshuler LL, et al. Placental passage of antidepressant medications. <i>Am J Psychiatry.</i> 2003;160(5):993-996.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/12727706/pubmed" id="12727706" target="_blank">12727706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23152227">
<a name="23152227"></a>Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. <i>Cochrane Database Syst Rev</i>. 2012;11:CD004851. doi:10.1002/14651858.CD004851.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/23152227/pubmed" id="23152227" target="_blank">23152227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.2019a">
<a name="Hirsch.2019a"></a>Hirsch M, Birnbaum RJ. Discontinuing antidepressant medications in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 29, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.2019b">
<a name="Hirsch.2019b"></a>Hirsch M, Birnbaum RJ. Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.2019c">
<a name="Hirsch.2019c"></a>Hirsch M, Birnbaum RJ. Switching antidepressant medications in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 9, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10812529">
<a name="10812529"></a>Hostetter A, Stowe ZN, Strader JR Jr, et al. Dose of selective serotonin uptake inhibitors across pregnancy: Clinical implications. <i>Depress Anxiety.</i> 2000;11(2):51-57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/10812529/pubmed" id="10812529" target="_blank">10812529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31030620">
<a name="31030620"></a>Hudd TR, Blake CS, Rimola-Dejesus Y, Nguyen TT, Zaiken K. A case report of serotonin syndrome in a patient on selective serotonin reuptake inhibitor (SSRI) monotherapy. <i>J Pharm Pract</i>. 2020;33(2):206-212. doi:10.1177/0897190019841742<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/31030620/pubmed" id="31030620" target="_blank">31030620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27378473">
<a name="27378473"></a>Ismaili E, Walsh S, O'Brien PMS, et al. Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): auditable standards for diagnosis and management of premenstrual disorder. <i>Arch Womens Ment Health</i>. 2016;19(6):953-958. doi:10.1007/s00737-016-0631-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/27378473/pubmed" id="27378473" target="_blank">27378473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27249090">
<a name="27249090"></a>Issari Y, Jakubovski E, Bartley CA, Pittenger C, Bloch MH. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. <i>J Clin Psychiatry</i>. 2016;77(5):e605-e611. doi:10.4088/JCP.14r09758<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/27249090/pubmed" id="27249090" target="_blank">27249090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16896026">
<a name="16896026"></a>Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. <i>Ann Pharmacother</i>. 2006;40(9):1618-1622. doi:10.1345/aph.1G293<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/16896026/pubmed" id="16896026" target="_blank">16896026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32619827">
<a name="32619827"></a>Javelot H, Fichter A, Meyer G, Michel B, Hingray C. A case of paroxetine-induced antidepressant discontinuation syndrome related to pregnancy: time to redefine the syndrome? <i>Psychiatry Res</i>. 2020;291:113259. doi:10.1016/j.psychres.2020.113259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/32619827/pubmed" id="32619827" target="_blank">32619827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30501420">
<a name="30501420"></a>Jha MK, Rush AJ, Trivedi MH. When discontinuing SSRI antidepressants is a challenge: management tips. <i>Am J Psychiatry</i>. 2018;175(12):1176-1184. doi:10.1176/appi.ajp.2018.18060692<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/30501420/pubmed" id="30501420" target="_blank">30501420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29955469">
<a name="29955469"></a>Jing E, Straw-Wilson K. Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: a narrative literature review. <i>Ment Health Clin</i>. 2016;6(4):191-196. doi:10.9740/mhc.2016.07.191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/29955469/pubmed" id="29955469" target="_blank">29955469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25081580">
<a name="25081580"></a>Katzman MA, Bleau P, Blier P, et al; Canadian Anxiety Guidelines Initiative Group. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(suppl 1):S1. doi:10.1186/1471-244X-14-S1-S1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/25081580/pubmed" id="25081580" target="_blank">25081580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Keller.2001">
<a name="Keller.2001"></a>Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial. <i>J Am Acad Child Adolesc Psychiatry.</i> 2001;40(7):762-772.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12668373">
<a name="12668373"></a>Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. <i>Am J Psychiatry</i>. 2003;160(4):790-792. doi:10.1176/appi.ajp.160.4.790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/12668373/pubmed" id="12668373" target="_blank">12668373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30247774">
<a name="30247774"></a>Khanassov V, Hu J, Reeves D, van Marwijk H. Selective serotonin reuptake inhibitor and selective serotonin and norepinephrine reuptake inhibitor use and risk of fractures in adults: a systematic review and meta-analysis. <i>Int J Geriatr Psychiatry</i>. 2018;33(12):1688-1708. doi:10.1002/gps.4974<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/30247774/pubmed" id="30247774" target="_blank">30247774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Khera.2020">
<a name="Khera.2020"></a>Khera M, Cunningham GR. Treatment of male sexual dysfunction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 11, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27993931">
<a name="27993931"></a>Kirkham J, Seitz D. Evidence of ocular side effects of SSRIs and new warnings. <i>Evid Based Ment Health</i>. 2017;20(1):27. doi:10.1136/eb-2016-102528<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/27993931/pubmed" id="27993931" target="_blank">27993931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9135392">
<a name="9135392"></a>Kirwan JF, Subak-Sharpe I, Teimory M. Bilateral acute angle closure glaucoma after administration of paroxetine. <i>Br J Ophthalmol</i>. 1997;81(3):252. doi:10.1136/bjo.81.3.252<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/9135392/pubmed" id="9135392" target="_blank">9135392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15654172">
<a name="15654172"></a>Koo JR, Yoon JY, Joo MH, et al. Treatment of depression and effect of antidepression treatment on nutritional status in chronic hemodialysis patients. <i>Am J Med Sci</i>. 2005;329(1):1-5. doi:10.1097/00000441-200501000-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/15654172/pubmed" id="15654172" target="_blank">15654172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11324355">
<a name="11324355"></a>Kopp R, Kunitz O, Baumert JH, Rossaint R. A patient with nodal tachycardia after general anesthesia during medication with a selective serotonin reuptake inhibitor [in German]. <i>Anasthesiol Intensivmed Notfallmed Schmerzther</i>. 2001;36(3):184-187. doi:10.1055/s-2001-11822<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/11324355/pubmed" id="11324355" target="_blank">11324355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17849776">
<a name="17849776"></a>Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB; American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. <i>Am J Psychiatry</i>. 2007;164(7)(suppl):S5-S53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/17849776/pubmed" id="17849776" target="_blank">17849776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21948719">
<a name="21948719"></a>Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. <i>CMAJ</i>. 2011;183(16):1835-1843. doi:10.1503/cmaj.100912<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/21948719/pubmed" id="21948719" target="_blank">21948719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16026177">
<a name="16026177"></a>Lai H, Tolat R. Paroxetine-related tremor. <i>Geriatrics</i>. 2005;60(7):18-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/16026177/pubmed" id="16026177" target="_blank">16026177</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10755580">
<a name="10755580"></a>Lake MB, Birmaher B, Wassick S, Mathos K, Yelovich AK. Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence. <i>J Child Adolesc Psychopharmacol</i>. 2000;10(1):35-38. doi:10.1089/cap.2000.10.35<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/10755580/pubmed" id="10755580" target="_blank">10755580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31078196">
<a name="31078196"></a>Lanza di Scalea T, Pearlstein T. Premenstrual dysphoric disorder. <i>Med Clin North Am</i>. 2019;103(4):613-628. doi:10.1016/j.mcna.2019.02.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/31078196/pubmed" id="31078196" target="_blank">31078196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30130711">
<a name="30130711"></a>Lee YK, Shin JS, Kim Y, et al. Antidepressants-related cardiovascular adverse events using the adverse event reporting system. <i>Psychiatry Res</i>. 2018;268:441-446. doi:10.1016/j.psychres.2018.07.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/30130711/pubmed" id="30130711" target="_blank">30130711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31475669">
<a name="31475669"></a>Leerssen ECM, Tak RO, Breur JMPJ. Severe transient neonatal long QT syndrome due to maternal paroxetine usage: a case report. <i>Cardiol Young</i>. 2019;29(10):1300-1301. doi:10.1017/S1047951119001938<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/31475669/pubmed" id="31475669" target="_blank">31475669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18056231">
<a name="18056231"></a>Leon AC. The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses. <i>Am J Psychiatry</i>. 2007;164(12):1786-1789. doi:10.1176/appi.ajp.2007.07050775<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/18056231/pubmed" id="18056231" target="_blank">18056231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9108816">
<a name="9108816"></a>Lewis CF, DeQuardo JR, DuBose C, Tandon R. Acute angle-closure glaucoma and paroxetine. <i>J Clin Psychiatry</i>. 1997;58(3):123-124. doi:10.4088/jcp.v58n0307b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/9108816/pubmed" id="9108816" target="_blank">9108816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11838629">
<a name="11838629"></a>Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. <i>J Clin Psychiatry</i>. 2002;63(1):66-74.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/11838629/pubmed" id="11838629" target="_blank">11838629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8804257">
<a name="8804257"></a>Liu BA, Mittmann N, Knowles SR, Shear NH. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. <i>CMAJ</i>. 1996;155(5):519-527.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/8804257/pubmed" id="8804257" target="_blank">8804257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35760074">
<a name="35760074"></a>Liu Q, Gao H, Huang Y, et al. Comparison of fluoxetine with other selective serotonin reuptake inhibitors in the treatment of premature ejaculation: a systematic review and meta-analysis. <i>Andrologia.</i> 2022;54(8):e14500. doi:10.1111/and.14500<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/35760074/pubmed" id="35760074" target="_blank">35760074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17919277">
<a name="17919277"></a>Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. <i>Aliment Pharmacol Ther</i>. 2008;27(1):31-40. doi:10.1111/j.1365-2036.2007.03541.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/17919277/pubmed" id="17919277" target="_blank">17919277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26150613">
<a name="26150613"></a>Maia JM, Guedes F, Aragão I, Cardoso T. Eosinophilic pneumonia presenting as life-threatening ARDS. <i>BMJ Case Rep</i>. 2015;2015:bcr2014207379. doi:10.1136/bcr-2014-207379<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/26150613/pubmed" id="26150613" target="_blank">26150613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27486149">
<a name="27486149"></a>MacQueen GM, Frey BN, Ismail Z, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 6. special populations: youth, women, and the elderly. <i>Can J Psychiatry</i>. 2016;61(9):588-603. doi:10.1177/0706743716659276<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/27486149/pubmed" id="27486149" target="_blank">27486149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23450307">
<a name="23450307"></a>Mameli C, Tadini G, Cattaneo D, Cerini C, Zuccotti GV. Acute generalized exanthematous pustulosis induced by paroxetine in an adolescent girl. <i>Acta Derm Venereol</i>. 2013;93(6):733-734. doi:10.2340/00015555-1559<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/23450307/pubmed" id="23450307" target="_blank">23450307</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8968300">
<a name="8968300"></a>Mancini C, Ameringen MV. Paroxetine in social phobia. <i>J Clin Psychiatry</i>. 1996;57(11):519-522.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/8968300/pubmed" id="8968300" target="_blank">8968300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24094459">
<a name="24094459"></a>Mannesse CK, Jansen PA, Van Marum RJ, et al. Characteristics, prevalence, risk factors, and underlying mechanism of hyponatremia in elderly patients treated with antidepressants: a cross-sectional study. <i>Maturitas</i>. 2013;76(4):357-363. doi:10.1016/j.maturitas.2013.08.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/24094459/pubmed" id="24094459" target="_blank">24094459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11230000">
<a name="11230000"></a>Margolese HC, Chouinard G, Beauclair L, Rubino M. Cutaneous vasculitis induced by paroxetine. <i>Am J Psychiatry</i>. 2001;158(3):497. doi:10.1176/appi.ajp.158.3.497<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/11230000/pubmed" id="11230000" target="_blank">11230000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19965920">
<a name="19965920"></a>Marshall AM, Nommsen-Rivers LA, Hernandez LL, et al. Serotonin transport and metabolism in the mammary gland modulates secretory activation and involution. <i>J Clin Endocrinol Metab.</i> 2010;95(2):837-846.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/19965920/pubmed" id="19965920" target="_blank">19965920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16892419">
<a name="16892419"></a>Marshall RD, Lewis-Fernandez R, Blanco C, et al. A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. <i>Depress Anxiety</i>. 2007;24(2):77-84. doi: 10.1002/da.20176.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/16892419/pubmed" id="16892419" target="_blank">16892419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15289250">
<a name="15289250"></a>Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D. Age effects on antidepressant-induced manic conversion. <i>Arch Pediatr Adolesc Med</i>. 2004;158(8):773-780. doi:10.1001/archpedi.158.8.773<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/15289250/pubmed" id="15289250" target="_blank">15289250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30170040">
<a name="30170040"></a>Masarwa R, Bar-Oz B, Gorelik E, Reif S, Perlman A, Matok I. Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis. <i>Am J Obstet Gynecol</i>. 2019;220(1):57.e1-57.e13. doi:10.1016/j.ajog.2018.08.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/30170040/pubmed" id="30170040" target="_blank">30170040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10941349">
<a name="10941349"></a>Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. <i>Medicine (Baltimore)</i>. 2000;79(4):201-209. doi:10.1097/00005792-200007000-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/10941349/pubmed" id="10941349" target="_blank">10941349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16858890">
<a name="16858890"></a>Mera MT, Pérez BV, Fernández RO, Iglesias JF. Hypersensitivity to paroxetine. <i>Allergol Immunopathol (Madr)</i>. 2006;34(3):125-126. doi:10.1016/s0301-0546(06)73527-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/16858890/pubmed" id="16858890" target="_blank">16858890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14745552">
<a name="14745552"></a>Merlob P, Stahl B, Sulkes J. Paroxetine during breast-feeding: infant weight gain and maternal adherence to counsel. <i>Eur J Pediatrm.</i> 2004;163(3):135-139.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/14745552/pubmed" id="14745552" target="_blank">14745552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16974194">
<a name="16974194"></a>Misri S, Corral M, Wardrop AA, Kendrick K. Quetiapine augmentation in lactation: a series of case reports. <i>J Clin Psychopharmacol</i>. 2006;26(5):508-511.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/16974194/pubmed" id="16974194" target="_blank">16974194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11105735">
<a name="11105735"></a>Misri S, Kim J, Riggs KW, Kostaras X. Paroxetine levels in postpartum depressed women, breast milk, and infant serum. <i>J Clin Psychiatry</i>. 2000;61(11):828-832.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/11105735/pubmed" id="11105735" target="_blank">11105735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8909336">
<a name="8909336"></a>Mithani H, Hurwitz TA. Paroxetine-induced angioedema and tongue swelling. <i>J Clin Psychiatry</i>. 1996;57(10):486.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/8909336/pubmed" id="8909336" target="_blank">8909336</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31591339">
<a name="31591339"></a>Montejo AL, Prieto N, de Alarcón R, Casado-Espada N, de la Iglesia J, Montejo L. Management strategies for antidepressant-related sexual dysfunction: a clinical approach. <i>J Clin Med</i>. 2019;8(10):1640. doi:10.3390/jcm8101640<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/31591339/pubmed" id="31591339" target="_blank">31591339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9292833">
<a name="9292833"></a>Montejo-González AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. <i>J Sex Marital Ther</i>. 1997;23(3):176-194. doi:10.1080/00926239708403923<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/9292833/pubmed" id="9292833" target="_blank">9292833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21179515">
<a name="21179515"></a>Moore TJ, Glenmullen J, Furberg CD. Prescription drugs associated with reports of violence towards others. <i>PLoS One</i>. 2010;5(12):e15337. doi:10.1371/journal.pone.0015337<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/21179515/pubmed" id="21179515" target="_blank">21179515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11221498">
<a name="11221498"></a>Morrison J, Remick RA, Leung M, Wrixon KJ, Bebb RA. Galactorrhea induced by paroxetine. <i>Can J Psychiatry</i>. 2001;46(1):88-89.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/11221498/pubmed" id="11221498" target="_blank">11221498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14581256">
<a name="14581256"></a>Movig KL, Janssen MW, de Waal Malefijt J, Kabel PJ, Leufkens HG, Egberts AC. Relationship of serotonergic antidepressants and need for blood transfusion in orthopedic surgical patients. <i>Arch Intern Med</i>. 2003;163(19):2354-2358. doi:10.1001/archinte.163.19.2354<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/14581256/pubmed" id="14581256" target="_blank">14581256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30397569">
<a name="30397569"></a>Mullen S. Major depressive disorder in children and adolescents. <i>Ment Health Clin</i>. 2018;8(6):275-283. doi:10.9740/mhc.2018.11.275<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/30397569/pubmed" id="30397569" target="_blank">30397569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25175904">
<a name="25175904"></a>Mullish BH, Kabir MS, Thursz MR, Dhar A. Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. <i>Aliment Pharmacol Ther</i>. 2014;40(8):880-892. doi:10.1111/apt.12925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/25175904/pubmed" id="25175904" target="_blank">25175904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22859791">
<a name="22859791"></a>Nagler EV, Webster AC, Vanholder R, Zoccali C. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). <i>Nephrol Dial Transplant</i>. 2012;27(10):3736-3745. doi:10.1093/ndt/gfs295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/22859791/pubmed" id="22859791" target="_blank">22859791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28859218">
<a name="28859218"></a>Näslund J, Hieronymus F, Emilsson JF, Lisinski A, Nilsson S, Eriksson E. Incidence of early anxiety aggravation in trials of selective serotonin reuptake inhibitors in depression. <i>Acta Psychiatr Scand</i>. 2017;136(4):343-351. doi:10.1111/acps.12784<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/28859218/pubmed" id="28859218" target="_blank">28859218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22132433">
<a name="22132433"></a>National Collaborating Centre for Mental Health (NCCMH). Depression: The Treatment and Management of Depression in Adults (Updated Edition). National Institute for Health &amp; Clinical Excellence (NICE). 2010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/22132433/pubmed" id="22132433" target="_blank">22132433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Obsessive-compulsive disorder and body dysmorphic disorder: treatment. https://www.nice.org.uk/guidance/cg31. Published November 2005. Accessed June 19, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21453380">
<a name="21453380"></a>Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. <i>J Am Geriatr Soc</i>. 2011;59(4):577-585. doi:10.1111/j.1532-5415.2011.03355.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/21453380/pubmed" id="21453380" target="_blank">21453380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23624686">
<a name="23624686"></a>Nevatte T, O'Brien PM, Bäckström T, et al; Consensus Group of the International Society for Premenstrual Disorders. ISPMD consensus on the management of premenstrual disorders. Arch Womens Ment Health. 2013;16(4):279-291. doi:10.1007/s00737-013-0346-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/23624686/pubmed" id="23624686" target="_blank">23624686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30407100">
<a name="30407100"></a>Ng QX, Venkatanarayanan N, Ho CYX, Sim WS, Lim DY, Yeo WS. Selective serotonin reuptake inhibitors and persistent pulmonary hypertension of the newborn: an update meta-analysis. <i>J Womens Health (Larchmt)</i>. 2019;28(3):331-338. doi:10.1089/jwh.2018.7319<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/30407100/pubmed" id="30407100" target="_blank">30407100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20354688">
<a name="20354688"></a>Nielsen AG, Pedersen RS, Noehr-Jensen L, Damkier P, Brosen K. Two separate dose-dependent effects of paroxetine: mydriasis and inhibition of tramadol's O-demethylation via CYP2D6. <i>Eur J Clin Pharmacol</i>. 2010;66(7):655-660. doi:10.1007/s00228-010-0803-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/20354688/pubmed" id="20354688" target="_blank">20354688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18501054">
<a name="18501054"></a>Nishida T, Wada M, Wada M, Ito H, Narabayashi M, Onishi H. Activation syndrome caused by paroxetine in a cancer patient. <i>Palliat Support Care</i>. 2008;6(2):183-185. doi:10.1017/S1478951508000278<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/18501054/pubmed" id="18501054" target="_blank">18501054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11475200">
<a name="11475200"></a>Nordeng H, Bergsholm YK, Bøhler E, Spigset O. The transfer of selective serotonin reuptake inhibitors to human milk. <i>Tidsskr Nor Laegeforen</i>. 2001;121(2):199-203.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/11475200/pubmed" id="11475200" target="_blank">11475200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23459282">
<a name="23459282"></a>Ogle NR, Akkerman SR. Guidance for the discontinuation or switching of antidepressant therapies in adults. <i>J Pharm Pract.</i> 2013;26(4):389-396. doi: 10.1177/0897190012467210.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/23459282/pubmed" id="23459282" target="_blank">23459282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22832136">
<a name="22832136"></a>Ono S, Suzuki Y, Someya T. Prolongation of idiopathic thrombocytopenic purpura associated with paroxetine administration. <i>Gen Hosp Psychiatry</i>. 2013;35(2). doi:10.1016/j.genhosppsych.2012.06.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/22832136/pubmed" id="22832136" target="_blank">22832136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18460039">
<a name="18460039"></a>Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. <i>Br J Clin Pharmacol</i>. 2008;66(1):76-81. doi:10.1111/j.1365-2125.2008.03154.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/18460039/pubmed" id="18460039" target="_blank">18460039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25572308">
<a name="25572308"></a>Orsolini L, Bellantuono C. Serotonin reuptake inhibitors and breastfeeding: a systematic review. <i>Hum Psychopharmacol</i>. 2015;30(1):4-20. doi:10.1002/hup.2451<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/25572308/pubmed" id="25572308" target="_blank">25572308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16415707">
<a name="16415707"></a>Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. <i>J Clin Psychopharmacol</i>. 2006;26(1):56-60. doi:10.1097/01.jcp.0000195042.62724.76<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/16415707/pubmed" id="16415707" target="_blank">16415707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26667012">
<a name="26667012"></a>Patel R, Reiss P, Shetty H, et al. Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study. <i>BMJ Open</i>. 2015;5(12):e008341. doi:10.1136/bmjopen-2015-008341<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/26667012/pubmed" id="26667012" target="_blank">26667012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Paxil.1">
<a name="Paxil.1"></a>Paxil (paroxetine) [prescribing information]. Weston, FL: Apotex Corp; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Paxil.4">
<a name="Paxil.4"></a>Paxil (paroxetine) [prescribing information]. Weston, FL: Apotex Corp; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Paxil.2">
<a name="Paxil.2"></a>Paxil CR (paroxetine) [prescribing information]. Weston, FL: Apotex Corp; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Paxil.3">
<a name="Paxil.3"></a>Paxil CR (paroxetine) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pexeva.1">
<a name="Pexeva.1"></a>Pexeva (paroxetine) [prescribing information]. Miami, FL: Noven Therapeutics; July 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pexeva.2">
<a name="Pexeva.2"></a>Pexeva (paroxetine mesylate) [prescribing information]. Roswell, GA: Sebela Pharmaceutical Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pexeva.3">
<a name="Pexeva.3"></a>Pexeva (paroxetine mesylate) [prescribing information]. Roswell, GA: Sebela Pharmaceutical Inc; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Phillips.2019">
<a name="Phillips.2019"></a>Phillips KA. Body dysmorphic disorder: Choosing treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 19, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18325859">
<a name="18325859"></a>Phillips KA, Hollander E. Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach. <i>Body Image</i>. 2008;5(1):13-27. doi:10.1016/j.bodyim.2007.12.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/18325859/pubmed" id="18325859" target="_blank">18325859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29557689">
<a name="29557689"></a>Pogliani L, Baldelli S, Cattaneo D, et al. Selective serotonin reuptake inhibitors' passage into human milk of lactating women. <i>J Matern Fetal Neonatal Med</i>. 2019;32(18):3020-3025. doi:10.1080/14767058.2018.1455180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/29557689/pubmed" id="29557689" target="_blank">29557689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11411817">
<a name="11411817"></a>Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial [published correction appears in <i>J Clin Psychiatry</i>. 2001;62(8):658]. <i>J Clin Psychiatry</i>. 2001;62(5):350-357.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/11411817/pubmed" id="11411817" target="_blank">11411817</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15704999">
<a name="15704999"></a>Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. <i>J Clin Psychiatry</i>. 2005;66(2):148-158. doi:10.4088/jcp.v66n0201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/15704999/pubmed" id="15704999" target="_blank">15704999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22176943">
<a name="22176943"></a>Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. AACAP. <i>J Am Acad Child Adolesc Psychiatry</i>. 2012;51(1):98-113. doi:10.1016/j.jaac.2011.09.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/22176943/pubmed" id="22176943" target="_blank">22176943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22638709">
<a name="22638709"></a>Rabenda V, Nicolet D, Beaudart C, Bruyère O, Reginster JY. Relationship between use of antidepressants and risk of fractures: a meta-analysis. <i>Osteoporosis International</i>. 2013;24(1):121-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/22638709/pubmed" id="22638709" target="_blank">22638709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9818637">
<a name="9818637"></a>Rand EH. Priapism in a patient taking sertraline. <i>J Clin Psychiatry</i>. 1998;59(10):538. doi:10.4088/jcp.v59n1007e<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/9818637/pubmed" id="9818637" target="_blank">9818637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26156519">
<a name="26156519"></a>Reefhuis J, Devine O, Friedman JM, Louik C, Honein MA; National Birth Defects Prevention Study. Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports. <i>BMJ</i>. 2015;351:h3190. doi:10.1136/bmj.h3190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/26156519/pubmed" id="26156519" target="_blank">26156519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20553304">
<a name="20553304"></a>Reeves RR, Ladner ME. Antidepressant-induced suicidality: an update. <i>CNS Neurosci Ther</i>. 2010;16(4):227-234. doi:10.1111/j.1755-5949.2010.00160.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/20553304/pubmed" id="20553304" target="_blank">20553304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17242321">
<a name="17242321"></a>Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. <i>Arch Intern Med</i>. 2007;167(2):188-194. doi:10.1001/archinte.167.2.188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/17242321/pubmed" id="17242321" target="_blank">17242321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22659406">
<a name="22659406"></a>Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. <i>Bone</i>. 2012;51(3):606-613.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/22659406/pubmed" id="22659406" target="_blank">22659406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21729172">
<a name="21729172"></a>Rodríguez-Pazos L, Gómez-Bernal S, Montero I, Rodríguez-Granados M, Toribio J. Erythema multiforme photoinduced by paroxetine and herpes simplex virus. <i>Photodermatol Photoimmunol Photomed</i>. 2011;27(4):219-221. doi:10.1111/j.1600-0781.2011.00600.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/21729172/pubmed" id="21729172" target="_blank">21729172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10504818">
<a name="10504818"></a>Rosenberg DR, Stewart CM, Fitzgerald KD, et al. Paroxetine open-label treatment of pediatric outpatients with obsessive-compulsive disorder. <i>J Am Acad Child Adolesc Psychiatry.</i> 1999;38(9):1180-1185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/10504818/pubmed" id="10504818" target="_blank">10504818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18468624">
<a name="18468624"></a>Rottach KG, Schaner BM, Kirch MH, et al. Restless legs syndrome as side effect of second generation antidepressants. <i>J Psychiatr Res</i>. 2008;43(1):70-75. doi:10.1016/j.jpsychires.2008.02.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/18468624/pubmed" id="18468624" target="_blank">18468624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23979084">
<a name="23979084"></a>Sachs HC; Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-e809.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/23979084/pubmed" id="23979084" target="_blank">23979084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16553536">
<a name="16553536"></a>Safer DJ, Zito JM. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. <i>J Child Adolesc Psychopharmacol</i>. 2006;16(1-2):159-169. doi:10.1089/cap.2006.16.159<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/16553536/pubmed" id="16553536" target="_blank">16553536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9021005">
<a name="9021005"></a>Sanz-Fuentenebro FJ, Huidobro A, Tejadas-Rivas A. Restless legs syndrome and paroxetine. <i>Acta Psychiatr Scand</i>. 1996;94(6):482-484. doi:10.1111/j.1600-0447.1996.tb09896.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/9021005/pubmed" id="9021005" target="_blank">9021005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16683860">
<a name="16683860"></a>Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. <i>J Clin Psychiatry</i>. 2006;67(Suppl 4):27-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/16683860/pubmed" id="16683860" target="_blank">16683860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32238008">
<a name="32238008"></a>Schoretsanitis G, Spigset O, Stingl JC, Deligiannidis KM, Paulzen M, Westin AA. The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis. <i>Expert Opin Drug Metab Toxicol</i>. 2020;16(5):431-440. doi:10.1080/17425255.2020.1750598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/32238008/pubmed" id="32238008" target="_blank">32238008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26819231">
<a name="26819231"></a>Sharma T, Guski LS, Freund N, Gøtzsche PC. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. <i>BMJ</i>. 2016;352:i65. doi:10.1136/bmj.i65<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/26819231/pubmed" id="26819231" target="_blank">26819231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15014601">
<a name="15014601"></a>Shelton RC. Steps following attainment of remission: discontinuation of antidepressant therapy. <i>Prim Care Companion J Clin Psychiatry</i>. 2001;3(4):168-174.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/15014601/pubmed" id="15014601" target="_blank">15014601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34961344">
<a name="34961344"></a>Shindel AW, Althof SE, Carrier S, et al. Disorders of ejaculation: an AUA/SMSNA guideline. <i>J Urol</i>. 2022;207(3):504-512. doi:10.1097/JU.0000000000002392<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/34961344/pubmed" id="34961344" target="_blank">34961344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Siris.2019">
<a name="Siris.2019"></a>Siris SG, Braga RJ. Anxiety in schizophrenia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 19, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31808410">
<a name="31808410"></a>Siroosbakht S, Rezakhaniha S, Rezakhaniha B. Which of available selective serotonin reuptake inhibitors (SSRIs) is more effective in treatment of premature ejaculation? A randomized clinical trial. <i>Int Braz J Urol</i>. 2019;45(6):1209-1215. doi:10.1590/S1677-5538.IBJU.2019.0121<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/31808410/pubmed" id="31808410" target="_blank">31808410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25107421">
<a name="25107421"></a>Slaton RM, Champion MN, Palmore KB. A review of paroxetine for the treatment of vasomotor symptoms. <i>J Pharm Pract</i>. 2015;28(3):266-274. doi: 10.1177/0897190014544785.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/25107421/pubmed" id="25107421" target="_blank">25107421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31035856">
<a name="31035856"></a>Slomian J, Honvo G, Emonts P, Reginster JY, Bruyère O. Consequences of maternal postpartum depression: a systematic review of maternal and infant outcomes. <i>Womens Health (Lond)</i>. 2019;15:1745506519844044. doi:10.1177/1745506519844044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/31035856/pubmed" id="31035856" target="_blank">31035856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29210786">
<a name="29210786"></a>Smith MM, Smith BB, Lahr BD, et al. Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors are not associated with bleeding or transfusion in cardiac surgical patients. <i>Anesth Analg</i>. 2018;126(6):1859-1866. doi:10.1213/ANE.0000000000002668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/29210786/pubmed" id="29210786" target="_blank">29210786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30964616">
<a name="30964616"></a>Sobieraj DM, Baker WL, Martinez BK, et al. <i>Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults</i>. Rockville (MD): Agency for Healthcare Research and Quality (US); 2019. doi:10.23970/AHRQEPCCER215<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/30964616/pubmed" id="30964616" target="_blank">30964616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26204124">
<a name="26204124"></a>Sriraman NK, Melvin K, Meltzer-Brody S. ABM clinical protocol #18: use of antidepressants in breastfeeding mothers. <i>Breastfeed Med</i>. 2015;10(6):290-299.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/26204124/pubmed" id="26204124" target="_blank">26204124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10333979">
<a name="10333979"></a>Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. <i>J Affect Disord</i>. 1998;51(3):215-235. doi:10.1016/s0165-0327(98)00221-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/10333979/pubmed" id="10333979" target="_blank">10333979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12783913">
<a name="12783913"></a>Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. <i>JAMA.</i> 2003;289(21):2827-2834. doi: 10.1001/jama.289.21.2827.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/12783913/pubmed" id="12783913" target="_blank">12783913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16192581">
<a name="16192581"></a>Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. <i>J Clin Oncol</i>. 2005;23(28):6919-6930. doi: 10.1200/JCO.2005.10.081.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/16192581/pubmed" id="16192581" target="_blank">16192581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stein.1">
<a name="Stein.1"></a>Stein MB. Management of posttraumatic stress disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 17, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stein.2">
<a name="Stein.2"></a>Stein MB. Pharmacotherapy for social anxiety disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 17, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stein.3">
<a name="Stein.3"></a>Stein MB, Goin MK, Pollack MH, et al; American Psychiatric Association (APA). Practice guideline for the treatment of patients with panic disorder. 2nd ed. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/panicdisorder.pdf. Published January 2009. Accessed June 19, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9728642">
<a name="9728642"></a>Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. <i>JAMA</i>. 1998;280(8):708-713.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/9728642/pubmed" id="9728642" target="_blank">9728642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18628446">
<a name="18628446"></a>Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. <i>Ann Pharmacother.</i> 2008;42(9):1290-1297. doi: 10.1345/aph.1L066.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/18628446/pubmed" id="18628446" target="_blank">18628446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18759711">
<a name="18759711"></a>Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. <i>Expert Opin Drug Saf</i>. 2008;7(5):587-596. doi:10.1517/14740338.7.5.587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/18759711/pubmed" id="18759711" target="_blank">18759711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30676405">
<a name="30676405"></a>Sylvester C, Menke M, Gopalan P. Selective serotonin reuptake inhibitors and fertility: considerations for couples trying to conceive. <i>Harv Rev Psychiatry</i>. 2019;27(2):108-118. doi:10.1097/HRP.0000000000000204<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/30676405/pubmed" id="30676405" target="_blank">30676405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19254516">
<a name="19254516"></a>Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. <i>J Clin Psychiatry</i>. 2009;70(3):344-353. doi:10.4088/jcp.07m03780<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/19254516/pubmed" id="19254516" target="_blank">19254516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25737963">
<a name="25737963"></a>Taniguchi G, Miyajima M, Watanabe M, et al. Nonconvulsive status epilepticus in the elderly associated with newer antidepressants used at therapeutic doses: a report of three cases. <i>Epilepsy Behav Case Rep</i>. 2014;3:8-11. doi:10.1016/j.ebcr.2014.10.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/25737963/pubmed" id="25737963" target="_blank">25737963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16720068">
<a name="16720068"></a>Tanii H, Ichihashi K, Inoue K, Fujita K, Okazaki Y. Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2006;30(6):1176-1178. doi:10.1016/j.pnpbp.2006.04.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/16720068/pubmed" id="16720068" target="_blank">16720068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19491861">
<a name="19491861"></a>Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. <i>Am J Gastroenterol</i>. 2009;104(6):1475-1482. doi:10.1038/ajg.2009.128<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/19491861/pubmed" id="19491861" target="_blank">19491861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17088502">
<a name="17088502"></a>Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. <i>Arch Gen Psychiatry</i>. 2006;63(11):1217-23. doi:10.1001/archpsyc.63.11.1217<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/17088502/pubmed" id="17088502" target="_blank">17088502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20459370">
<a name="20459370"></a>Thibaut F, De La Barra F, Gordon H, Cosyns P, Bradford JM; WFSBP Task Force on Sexual Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of paraphilias. <i>World J Biol Psychiatry</i>. 2010;11(4):604-655. doi: 10.3109/15622971003671628.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/20459370/pubmed" id="20459370" target="_blank">20459370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28766108">
<a name="28766108"></a>Tomlin AM, Reith DM, Woods DJ, et al. A pharmacoepidemiology database system for monitoring risk due to the use of medicines by New Zealand primary care patients. <i>Drug Saf</i>. 2017;40(12):1259-1277. doi:10.1007/s40264-017-0579-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/28766108/pubmed" id="28766108" target="_blank">28766108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19958306">
<a name="19958306"></a>Tondo L, Vázquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. <i>Acta Psychiatr Scand</i>. 2010;121(6):404-414. doi:10.1111/j.1600-0447.2009.01514.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/19958306/pubmed" id="19958306" target="_blank">19958306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29185803">
<a name="29185803"></a>Uguz F. Better tolerance of citalopram in a breastfed infant who could not tolerate sertraline and paroxetine. <i>Breastfeed Med</i>. 2018;13(1):89-90. doi:10.1089/bfm.2017.0168<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/29185803/pubmed" id="29185803" target="_blank">29185803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24434531">
<a name="24434531"></a>Uguz F. Rapid weight gain associated with edema after use of paroxetine and venlafaxine: 2 case reports. <i>Clin Neuropharmacol</i>. 2014;37(1):34-35. doi:10.1097/WNF.0000000000000012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/24434531/pubmed" id="24434531" target="_blank">24434531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27575664">
<a name="27575664"></a>Uguz F, Arpaci N. Short-term safety of paroxetine and sertraline in breastfed infants: a retrospective cohort study from a university hospital. <i>Breastfeed Med</i>. 2016;11:487-489.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/27575664/pubmed" id="27575664" target="_blank">27575664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23312145">
<a name="23312145"></a>Uguz F, Sonmez EÖ. Neuroleptic malignant syndrome following combination of sertraline and paroxetine: a case report. <i>Gen Hosp Psychiatry</i>. 2013;35(3):327.e7-327.e8. doi:10.1016/j.genhosppsych.2012.11.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/23312145/pubmed" id="23312145" target="_blank">23312145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27663940">
<a name="27663940"></a>Varigonda AL, Jakubovski E, Bloch MH. Systematic review and meta-analysis: early treatment responses of selective serotonin reuptake inhibitors and clomipramine in pediatric obsessive-compulsive disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2016;55(10):851-859.e2. doi:10.1016/j.jaac.2016.07.768<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/27663940/pubmed" id="27663940" target="_blank">27663940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14742765">
<a name="14742765"></a>Velez LI, Shepherd G, Roth BA, Benitez FL. Serotonin syndrome with elevated paroxetine concentrations. <i>Ann Pharmacother</i>. 2004;38(2):269-272. doi:10.1345/aph.1D352<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/14742765/pubmed" id="14742765" target="_blank">14742765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22217958">
<a name="22217958"></a>Verma R, Balhara YP, Deshpande SN. Angular cheilitis after paroxetine treatment. <i>J Clin Psychopharmacol</i>. 2012;32(1):150-151. doi:10.1097/JCP.0b013e31823f878a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/22217958/pubmed" id="22217958" target="_blank">22217958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19743889">
<a name="19743889"></a>Ververs FF, Voorbij HA, Zwarts P, et al. Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy. <i>Clin Pharmacokinet.</i> 2009;48(10):677-683. doi: 10.2165/11318050-000000000-00000.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/19743889/pubmed" id="19743889" target="_blank">19743889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11147747">
<a name="11147747"></a>Votolato NA, Stern S, Caputo RM. Serotonergic antidepressants and urinary incontinence. <i>Int Urogynecol J Pelvic Floor Dysfunct</i>. 2000;11(6):386-388. doi:10.1007/s001920070009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/11147747/pubmed" id="11147747" target="_blank">11147747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30775508">
<a name="30775508"></a>Wadhwa R, Kumar M, Talegaonkar S, Vohora D. Serotonin reuptake inhibitors and bone health: a review of clinical studies and plausible mechanisms. <i>Osteoporos Sarcopenia</i>. 2017;3(2):75-81. doi:10.1016/j.afos.2017.05.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/30775508/pubmed" id="30775508" target="_blank">30775508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15520363">
<a name="15520363"></a>Wagner KD, Berard R, Stein MB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. <i>Arch Gen Psychiatry.</i> 2004;61(11):1153-1162. doi:10.1001/archpsyc.61.11.1153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/15520363/pubmed" id="15520363" target="_blank">15520363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17874351">
<a name="17874351"></a>Wakeno M, Okugawa G, Takekita Y, et al. Delirium associated with paroxetine in an elderly depressive patient: a case report. <i>Pharmacopsychiatry</i>. 2007;40(5):199-200. doi:10.1055/s-2007-985882<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/17874351/pubmed" id="17874351" target="_blank">17874351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26003261">
<a name="26003261"></a>Waldinger MD. Psychiatric disorders and sexual dysfunction. <i>Handb Clin Neurol</i>. 2015;130:469-489. doi:10.1016/B978-0-444-63247-0.00027-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/26003261/pubmed" id="26003261" target="_blank">26003261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9126089">
<a name="9126089"></a>Waldinger MD, Hengeveld MW, Zwinderman AH. Ejaculation-retarding properties of paroxetine in patients with primary premature ejaculation: a double-blind, randomized, dose-response study. <i>Br J Urol</i>. 1997;79(4):592-595.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/9126089/pubmed" id="9126089" target="_blank">9126089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11386492">
<a name="11386492"></a>Waldinger MD, Zwinderman AH, Olivier B. Antidepressants and ejaculation: a double-blind, randomized, placebo-controlled, fixed-dose study with paroxetine, sertraline, and nefazodone. <i>J Clin Psychopharmacol</i>. 2001;21(3):293-297.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/11386492/pubmed" id="11386492" target="_blank">11386492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14961051">
<a name="14961051"></a>Waldinger MD, Zwinderman AH, Schweitzer DH, Olivier B. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. <i>Int J Impot Res</i>. 2004;16(4):369-381. doi:10.1038/sj.ijir.3901172<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/14961051/pubmed" id="14961051" target="_blank">14961051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32439401">
<a name="32439401"></a>Walter HJ, Bukstein OG, Abright AR, et al. Clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2020;59(10):1107-1124. doi:10.1016/j.jaac.2020.05.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/32439401/pubmed" id="32439401" target="_blank">32439401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27495351">
<a name="27495351"></a>Warden SJ, Fuchs RK. Do selective serotonin reuptake inhibitors (SSRIs) cause fractures? <i>Curr Osteoporos Rep</i>. 2016;14(5):211-218. doi:10.1007/s11914-016-0322-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/27495351/pubmed" id="27495351" target="_blank">27495351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16913164">
<a name="16913164"></a>Warner, CH, Bobo W, Warner C, et al. Antidepressant discontinuation syndrome. <i>Am Fam Physician</i>. 2006;74:449-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/16913164/pubmed" id="16913164" target="_blank">16913164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15169695">
<a name="15169695"></a>Weissman AM, Levy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. <i>Am J Psychiatry.</i> 2004;161(6):1066-1078. doi:10.1176/appi.ajp.161.6.1066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/15169695/pubmed" id="15169695" target="_blank">15169695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17373154">
<a name="17373154"></a>Welsh JP, Cusack CA, Ko C. Urticarial vasculitis secondary to paroxetine. <i>J Drugs Dermatol</i>. 2006;5(10):1012-1014.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/17373154/pubmed" id="17373154" target="_blank">17373154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22114630">
<a name="22114630"></a>Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of torsade de pointes. <i>Dtsch Arztebl Int</i>. 2011;108(41):687-693. doi:10.3238/arztebl.2011.0687<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/22114630/pubmed" id="22114630" target="_blank">22114630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28708853">
<a name="28708853"></a>Westin AA, Brekke M, Molden E, Skogvoll E, Spigset O. Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: changes in drug disposition. <i>PLoS One</i>. 2017;12(7):e0181082. doi:10.1371/journal.pone.0181082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/28708853/pubmed" id="28708853" target="_blank">28708853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29873955">
<a name="29873955"></a>Williams AJ, Lai Z, Knight S, Kamali M, Assari S, McInnis MG. Risk factors associated with antidepressant exposure and history of antidepressant-induced mania in bipolar disorder. <i>J Clin Psychiatry</i>. 2018;79(3):17m11765. doi:10.4088/JCP.17m11765<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/29873955/pubmed" id="29873955" target="_blank">29873955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28953843">
<a name="28953843"></a>Womersley K, Ripullone K, Agius M. What are the risks associated with different selective serotonin re-uptake inhibitors (SSRIs) to treat depression and anxiety in pregnancy? An evaluation of current evidence. <i>Psychiatr Danub</i>. 2017;29(suppl 3):629-644.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/28953843/pubmed" id="28953843" target="_blank">28953843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22240860">
<a name="22240860"></a>Yasui-Furukori N, Sato Y, Kato H, Kaneko S. Paroxetine-associated hypereosinophilia may clinically resemble a panic attack. <i>Clin Neuropharmacol</i>. 2012;35(1):47-48. doi:10.1097/WNF.0b013e31823da9a8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/22240860/pubmed" id="22240860" target="_blank">22240860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19701065">
<a name="19701065"></a>Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. <i>Obstet Gynecol.</i> 2009;114(3):703-713. doi: 10.1097/AOG.0b013e3181ba0632<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/19701065/pubmed" id="19701065" target="_blank">19701065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30606186">
<a name="30606186"></a>Zhang D, Cheng Y, Wu K, Ma Q, Jiang J, Yan Z. Paroxetine in the treatment of premature ejaculation: a systematic review and meta-analysis. <i>BMC Urol</i>. 2019;19(1):2. doi:10.1186/s12894-018-0431-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paroxetine-pediatric-drug-information/abstract-text/30606186/pubmed" id="30606186" target="_blank">30606186</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12681 Version 626.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
